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The RNA interference (RNAi) pathway is a cellular pathway which has roles in gene 
regulation and degradation of foreign RNA. RNAi can be exploited and used as a 
sequence specific and highly effective technique for the suppression of target genes. 
Previous research has found that plasmid based expression of short hairpin RNAs 
(shRNAs) within cells can result in cellular toxicity due to the continuous and high 
level of expression. In this study the optimisation of individual shRNAs known to be 
effective against H5N1 influenza virus was investigated, with the focus on the loop 
sequence of the shRNAs. This study initially looked at optimising the processing 
efficiency of a shRNA to the mature small interfering RNA (siRNA) in order to 
allow a reduction in the amount of shRNA expressed while retaining a high level of 
target suppression. In order to do this the artificial loop sequence (Brummelkamp et 
al., 2002) of two influenza A targeting shRNAs was replaced with loop sequences 
derived from highly expressed native chicken preliminary micro RNAs 
(pre-miRNAs). It was found that the use of a pre-miRNA derived loop sequence 
affects the efficiency at which a shRNA is processed in to the mature siRNA, as well 
as the suppressive activity of the shRNA. This effect was found to vary depending on 
the loop sequence and also the sequence of the siRNA stem.  
 
The high mutation rate of RNA viruses such as influenza allows escape from 
antiviral strategies which target only a single sequence; therefore it is necessary to 
target multiple sequences in order to prevent viral escape. Combinatorial RNAi 
(coRNAi) involves the expression of multiple RNAi inducing molecules in order to 
accomplish this. The second part of this study focused on the investigation of the 
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multiple transcription unit (MTU) strategy and the factors which affect the 
expression and suppressive activity of shRNAs within multiwarhead (MWH) 
constructs. The results showed no evidence that the positioning of shRNAs within a 
MWH has an effect on shRNA expression or individual suppressive activity, or the 
net suppressive activity of a MWH. Results showed that hairpin competition can 
cause a reduction in the individual suppressive activity of a hairpin, and that the 
incorporation of a weakly suppressing shRNA into a MWH can reduce the net 
suppressive activity of the construct. It is therefore important to carefully select 
shRNAs which will be incorporated into MTU constructs. Out of the MWHs 
produced none were found to have increased viral suppressive activity; however it is 
suggested that the presence of multiple target sequences would nevertheless increase 
the ability of the MWH to prevent viral escape. Future work is needed to confirm 
this. Research performed in this study aims to increase knowledge of the use of 
RNAi in the context of creating antiviral transgenes capable of simultaneously 
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CHAPTER 1. Introduction 
1.1 RNA Interference 
RNAi is a sequence specific method of cellular defence and regulation of gene 
expression which is naturally induced by double stranded RNA (dsRNA) produced 
during viral infection, and by microRNAs (miRNA). Artificially induced gene 
suppression was first produced using RNAi in petunia plants in 1990 (Napoli et al., 
1990), but at this time there was very little understanding of the mechanism behind 
the phenomenon. In 1998, Fire and colleagues (Fire et al., 1998) unearthed RNAi in 
the worm Caenorhabditis elegans and provided invaluable insight into the existence 
of an RNAi pathway. This discovery was followed by the identification and 
investigation of RNAi pathways in insects (Kennerdell and Carthew, 1998), plants 
(Hamilton and Baulcombe, 1999), mice (Bahramian and Zarbl, 1999), and humans 
(Elbashir et al., 2001a); as well as several other species. 
 
1.1.1 Natural induction by miRNAs 
Endogenously expressed primary miRNA transcripts (pri-miRNAs) are produced 
within the nucleus by RNA polymerase II (RNA pol II) transcription. They can be 
produced from independent genes and processed by Drosha into ~70 nucleotide (nt) 
pre-miRNAs (Lee et al., 2002b; Zeng and Cullen, 2003). Alternatively they can be 
spliced from the introns of protein-coding genes (Carthew and Sontheimer, 2009; 




The pre-miRNAs are transported into the cytoplasm by Exportin-5 (Bohnsack et al., 
2004; Lund et al., 2004; Yi et al., 2003) where Dicer cleaves the pre-miRNA to 
remove the loop, resulting in an ~21 nt miRNA duplex containing a 5‟ phosphate 
group and a 2 nt 3‟ overhang (Lee et al., 2003). The strand of the duplex selected for 
incorporation into the RNA Induced Silencing Complex (RISC) is the one with the 
least thermodynamically stable 5‟ end (Khvorova et al., 2003; Schwarz et al., 2003). 
This strand is known as the guide strand, and leads RISC to the target messenger 
RNA (mRNA). The complementary strand, known as the passenger strand, is 
degraded (Hammond et al., 2000). If the guide strand is identical in sequence to the 
target mRNA then the mRNA is cleaved and degraded. If there are a small number of 
mismatches between the target mRNA and the miRNA seed region, located at 
nucleotides 2-7 from the 5‟ end of the miRNA, then the mRNA is sequestered within 
p-bodies in the cell resulting in translational repression (Doench and Sharp, 2004; 
Khvorova et al., 2003; Kiriakidou et al., 2004; Lai, 2002; Lewis et al., 2003) (Figure 
1.1a). In miRNAs that have two effective strands the strands partner with separate 
RISCs and can both result in mRNA degradation or inhibition of translation (Ro et 
al., 2007). 
 
1.1.2 Artificial induction  
The exploitation of RNAi in order to investigate gene expression involves artificially 
inducing the degradation of a target mRNA. Several different types of molecules 
have been used to do this, including induction by long dsRNA, synthetic siRNAs 
(Figure 1.1c), and vector-based expression of shRNAs (Figure 1.1b). Firstly the use 




Figure 1.1 RNAi pathway 
(a) Endogenous miRNA sequences are transcribed to produce single or clusters of pri-miRNAs. 
Drosha processes the pri-miRNAs into the single or multiple pre-miRNAs from the transcript. 
Exportin-5 (Exp-5) enables the pre-miRNAs to exit the nucleus. In the cytoplasm Dicer cleavage 
removes the pre-miRNA loop, producing the mature miRNA duplex. The guide strand of the duplex 
binds the RNA induced silencing complex (RISC) and leads it to the target mRNA. If the guide strand 
and the target sequence are fully complimentary this results in cleavage of the mRNA. If the guide and 
target sequences contain mismatches in the seed region this results in translational repression. In 
miRNAs that have two effective strands the two strands partner with separate RISCs. (b) A plasmid 
expressing an shRNA is introduced into the cell via transfection or electroporation, and enters the 
nucleus. Transcription produces an shRNA, Exportin-5 enables the shRNA to leave the nucleus. The 
shRNA joins the natural RNAi pathway at the point of the pre-miRNA hairpin. (c) A synthetically 
produced siRNA duplex is introduced into the cell and joins the natural RNAi pathway at the point of 





















1.1.2.1 Long dsRNA 
As RNAi can be naturally induced by the dsRNA produced by viral infection, the use 
of dsRNA as a mechanism to artificially induce RNAi was explored. Research was  
performed in various species including plants (Baulcombe, 1999), flat worms 
(Sanchez Alvarado and Newmark, 1999), fruit flies (Kennerdell and Carthew, 1998; 
Misquitta and Paterson, 1999) and mosquitoes (Caplen et al., 2002) and found to be 
an effective method of inducing RNAi. Introduction of long dsRNA into cells results 
in the production of several siRNA duplexes which can lead to cleavage of the target 
mRNA in a highly sequence specific manner. 
 
An issue with the use of long dsRNA is that within mammalian cells lengths longer 
than 30 nt lead to induction of the interferon response (Elbashir et al., 2001a; Stark et 
al., 1998). Interferon synthesis occurs when the long dsRNA activates the protein 
kinase PKR (Manche et al., 1992) and 2‟,5‟-oligoadenylate synthetase (2‟,5‟-AS) 
(Minks et al., 1979) by binding to them. A halting of translation coupled with mRNA 
degradation is caused by activated PKRs phosphorylation of translation initiation 
factors eIF2α (Manche et al., 1992), and activation of 2‟5‟-AS dependent 
ribonuclease L by 2‟,5‟-AS (Minks et al., 1979) respectively. Induction of the 
interferon response results in global inhibition of mRNA translation (Stark et al., 
1998). Therefore it was found that long dsRNA was not an appropriate method of 
induction for use in mammals, and smaller dsRNA molecules (< 30 nt) were tested in 





Synthetically produced 21 and 22 nt molecules with 2 nt overhanging 3‟ ends that 
mimic the products of Dicer cleavage of dsRNA were found to produce 
sequence-specific mRNA degradation in lysates prepared from Drosophila embryos  
(Elbashir et al., 2001b). Molecules of this design were then investigated in cultured 
mammalian cells and were found to avoid induction of the interferon response 
(Elbashir et al., 2001a). In 2006 Marques and colleagues (Marques et al., 2006) 
found that blunt-ended siRNAs lacking the 2 nt 3‟ overhangs can induce an 
interferon response in mammalian cells through recognition by the retinoic acid 
inducible gene I helicase. 
 
Many different parameters must be considered in order to design effective siRNAs. 
Rules for selection were initially proposed in 2002 based on the first identified 
functional siRNAs (Elbashir et al., 2002). Knowledge gained from further research 
into the RNAi pathway including statistical analyses of experimentally determined 
efficiencies of siRNA libraries, culminated in the development of computer-based 
approaches for siRNA selection (Huesken et al., 2005; Reynolds et al., 2004; 
Saetrom and Snove, 2004). Although these approaches improved upon the empirical 
rules previously proposed, exceptions were found which showed there were still 
issues with their use (Birmingham et al., 2006; Reynolds et al., 2004; Zhao et al., 
2005). In order to be confident in the design of effective siRNAs, experimental 
approaches should be coupled with computer-based tools (Ito et al., 2005; Kasim et 
al., 2006; Zhao et al., 2005). General rules for siRNA design are that they contain a 
passenger strand and a guide strand that are paired to produce a duplex of 21-23 nt 
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containing 2 nt 3‟ overhangs. The guide strand of the duplex is incorporated into 
RISC while the passenger strand is destroyed (Leuschner et al., 2006; Matranga et 
al., 2005; Rand et al., 2005). 
 
There are several issues with using siRNAs to induce RNAi. In order for successful 
suppression to be produced siRNAs must be efficiently delivered to cells. This can 
be difficult as some cell types are resistant to transfection. In addition, the effect of 
siRNAs on the target gene is short-lived, lasting only 1-3 days in culture, preventing 
the use of this method for long-term gene suppression analysis (Chiu and Rana, 
2002; Holen et al., 2002).  
 
In order to overcome the limitations of siRNA induced RNAi much research has 
been done into the use of DNA vector based expression of shRNA. In 2003 the 
patent for the induction of RNAi in animal cells using DNA directed RNA (US 
6,573,099) such as shRNAs was co-awarded to Benitec Australia and the CSIRO 
(Graham, 2003).  
 
1.1.2.3 shRNA  
In 2002, Brummelkamp and colleagues (Brummelkamp et al., 2002) developed a 
vector based expression method labelled the pSUPER system, and used this to 
express shRNAs targeted to the endogenous CDH1 gene under the control of the 
RNA polymerase III (pol III) type III H1 promoter. Following the promoter 
sequence, the shRNA itself was composed of a 19 nt 5‟ sense strand identical to the 
target sequence, a spacer sequence (loop) of one of three tested lengths (5, 7 and 9 
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nt), a 19 nt 3‟ antisense strand directly complementary to the target sequence, and the 
RNA pol III type III H1 termination signal of five thymine residues in a row. 
Cleavage of the shRNA transcript at the termination site is after the second uridine 
residue therefore producing a 3‟ overhang of two uridine residues, as present on the 
ends of synthetic siRNAs (Brummelkamp et al., 2002). Importantly, they found that 
the shRNA containing the 9 nt length loop was as effective at reducing expression of 
the target gene CDH1 as the synthetic siRNA targeting the same sequence.  
 
The study by Brummelkamp and colleagues (Brummelkamp et al., 2002) made other 
important findings in addition to those previously discussed. They reported great 
difference in the effectiveness of shRNAs which differed only in the loop region 
(loops tested were of variable sequence and length), suggesting that the size and 
nucleotide sequence of the loop is very important. They also observed that the effects 
of shRNA induced suppression of the target gene remained present two months after 
stable transfection of cells, showing that shRNAs can produce a much longer-lasting 
suppression of gene expression than that produced by synthetic siRNAs. 
 
Since the initial work carried out in 2002 (Brummelkamp et al., 2002) there have 
been many other groups that have experimented with the use of vector based shRNA 
expression for specific gene suppression. Several viruses have been successfully 
targeted in vitro using shRNA expression vectors including avian influenza (AI) (Li 
et al., 2005), human immunodeficiency virus type 1 (HIV-1) (Lee et al., 2002a), 
hepatitis B virus (HBV) (Tang et al., 2003), Marek‟s disease virus (Chen et al., 2008; 
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Lambeth et al., 2009), and viral haemorrhagic septicaemia virus (Kim and Kim, 
2011).  
 
Commonly used promoters for shRNA expression include the RNA pol III type III 
promoters U6 and H1. These promoters result in high level expression of shRNAs 
and have specific initiation and termination sites, with termination occurring as a 
result of four to six consecutive uridine residues. Along with RNA pol III promoters, 
transfer RNA promoters are also used. Both pol III and transfer RNA promoters are 
naturally involved in the production of small cellular transcripts and therefore well 
suited to the expression of shRNAs (Brummelkamp et al., 2002; Kawasaki and Taira, 
2003; Paddison et al., 2002a). 
 
Along with the advantages of being able to express shRNAs from DNA vectors there 
are inherent risks. DNA vector based expression of shRNAs enables long term RNA 
interference in mammalian cells (Brummelkamp et al., 2002; Paddison et al., 2002a; 
Paddison et al., 2002b) while continuing to avoid induction of the interferon 
response (Brummelkamp et al., 2002; Kawasaki and Taira, 2003; McManus et al., 
2002b; Paddison et al., 2002a; Paddison et al., 2002b; Sui et al., 2002; Yu et al., 
2002). However, due to the continuous and high level expression of shRNAs from 
the commonly used RNA pol III promoters H1 and U6, there is danger of 





1.1.2.4 Toxicity  
The potential of high-level expression of shRNAs to overload native cellular 
machinery resulting in toxicity has huge implications for future antiviral strategies in 
animals and humans. In 2006 research in mice using adeno-associated virus vectors 
(Grimm et al., 2006) found that high-level U6 expression of shRNAs resulted in 
saturation of Exportin-5, resulting in the prevention of transport of endogenous 
pre-miRNAs out of the nucleus and causing death in 23 out of the 49 mice tested. 
Grimm and colleagues found that toxicity was dose dependent and could be avoided 
by decreasing the dosage of shRNA expression vectors administered to the mice, 
resulting in an effective and long-lasting inhibition of HBV.  
 
Another study that observed production of toxicity by expression of shRNAs from a 
U6 promoter was performed in human primary lymphocytes by An and colleagues in 
2006 (An et al., 2006). This study used lentiviral vectors and tested two RNA pol III 
promoters, the U6 promoter and the H1 promoter; and found that the decreased 
amount of shRNA transcript (six fold lower) produced by the weaker H1 promoter 
resulted in prevention of cytotoxicity. 
 
This research shows that the optimisation of shRNA strategies is important in order 
to avoid the risk of toxicity to cells, and resulting fatalities in organisms. The amount 
of shRNA transcript produced depends on the dose of the vector that expresses the 
shRNA and the expression strength of the promoter used to express the shRNA. The 
amount of siRNA transcript depends on these aforementioned factors, as well as the 
efficiency that the shRNA is processed into siRNA within the RNAi pathway. 
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Producing shRNAs that are more highly processed could enable the use of a 
promoter of lower expression strength, therefore reducing the risk of overloading the 
cellular machinery and the resulting toxicity while still obtaining an equivalent level 
of suppression. 
 
Overloading the native machinery of the cell is not the only issue present when 
artificially inducing RNAi, with evidence also having been found of off-target effects 
of siRNA and shRNA expression as a result of partial sequence homology to 
non-targeted mRNAs (Jackson and Linsley, 2004). Profiling studies have further 
researched this phenomenon and confirmed that partial sequence homology between  
the guide strand and a non-targeted mRNA was able to produce undesirable off-
target suppression of genes, with suppression believed to be a result of 6-7 nt of 
homology between the siRNA/shRNA sequence and the 3‟ untranslated region of the 
off-target mRNA (Birmingham et al., 2006; Fedorov et al., 2006; Jackson et al., 
2003; Jackson et al., 2006; Lim et al., 2005; Lin et al., 2005). Full sequence 
coverage of the genome of the chosen organism can be used to design molecules that 
do not share sequence homology with off-target mRNAs. 
 
1.1.2.5 Optimisation 
Research has been performed to optimise shRNA processing by designing shRNAs 
that are closer to the native pre-miRNA structure and therefore are predicted to pass 
more smoothly through the cellular RNAi pathway (Figure 1.2). This research has 
included the use of loop sequences derived from pre-miRNAs (miRloop shRNAs), 
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and also the development of „artificial pre-miRNAs‟ that are much closer mimics of 
the natural pre-miRNA structure.  
 
Loop sequences investigated thus far include human miR-17 (Schopman et al., 
2010), miR-25 (Schopman et al., 2010), and miR-30 (Boden et al., 2004; Hinton et 
al., 2008; Miyagishi et al., 2004; Zeng et al., 2002); mouse miR-26a (McManus et 
al., 2002b); and chicken miR-17 and miR-30 (Hinton et al., 2008). Results have 
shown that use of different loop sequences can improve or reduce the suppressive 
activity of shRNAs, and that the efficiency of any given loop varies based on the 
size, structure, and sequence of the loop (Schopman et al., 2010). It is not plausible 
to claim that any one loop is universally good, due to potential variables within 
shRNAs that affect how a loop may work; including the sequence and length of the 
stem itself (Schopman et al., 2010).  
 
Artificial pre-miRNAs are usually expressed from RNA pol II promoters because 
they are the natural promoters of most miRNAs (Lee et al., 2004). RNA pol II 
promoters include inducible and tissue-specific promoters that allow regulation of 
the expression of the RNA inducing molecule. They also result in much lower 
expression levels than pol III promoters. Artificial pre-miRNAs developed have 
included those where mismatches have been introduced into the duplex in order to 
mimic mismatches present in the pre-miRNA (Ely et al., 2008), and also those where 
the duplex has been kept fully complementary but is inserted into a pre-miRNA 
backbone such as that of human miR-30 (Li et al., 2007; Silva et al., 2005; Stegmeier 







Figure 1.2 Optimisation of individual shRNAs 
(a) A pre-miRNA contains an imperfectly paired duplex, with some mismatches producing bulges, the 
loop can contain both paired and unpaired regions. (b) A shRNA contains a perfectly paired duplex 
with a loop. The widely used standard loop is an artificial sequence consisting of a 9 nt loop with a 2 
nt paired area at the base (Brummelkamp et al., 2002). (c) One method of optimising an shRNA is the 
miRloop shRNA: choosing a pre-miRNA loop and using it to replace the shRNA loop sequence, but 
keeping the siRNA duplex perfectly complementary. (d) Another method of optimising a shRNA is 
the artificial pre-miRNA: using a loop sequence derived from a pre-miRNA and inserting mismatches 






• pre-miRNA derived loop sequence
• mismatches inserted into passenger strand
to produce bulges as in pre-miRNA
• pre-miRNA derived loop
• siRNA duplex kept perfectly complementary 
• standard 9 nt loop with 2 nt paired at base
• siRNA duplex kept perfectly complementary 
• loop with both paired and unpaired regions





1.1.3 Combinatorial RNAi 
Due to the high mutation rate of RNA viruses there is great risk of viruses escaping 
from vaccines or therapeutics where only a single sequence is targeted. Methods 
using RNAi against a single target face the same challenges as other monotherapies 
such as vaccines, and the sequence specificity of RNAi means that a single 
nucleotide change in a target can protect the mRNA from degradation and allow the 
mutant to escape (Randall et al., 2003; Wilson and Richardson, 2005), providing that 
mutant with a growth advantage in the face of pressure from RNAi (Boden et al., 
2003; Gitlin et al., 2002; Gitlin et al., 2005).  
 
A solution to this is to develop a strategy where multiple sequences within a single 
gene are targeted, or alternatively where sequences from several different genes are 
targeted. Targeting several different conserved sequences greatly increases the 
chance of resisting viral escape and creating an effective and long-lasting antiviral 
strategy. These multiple target strategies are known as coRNAi. 
 
In order to gain a better understanding of the potential of coRNAi to prevent escape 
of HIV-1 Leonard and Schaffer (Leonard and Schaffer, 2005) produced a 
computational model of HIV replication that takes into account details of HIV 
reproduction and vulnerability to RNAi. The model enabled prediction of the number 
of gene sequences required to be effectively targeted in order to obtain complete 
extinction of a targeted virus and therefore prevent any possibility of escape mutants. 
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It was predicted that targeting one viral sequence with average efficiency (70% 
probability of resulting in degradation of the target) would result in extinction of 
viral population in 0% of trials, whereas simultaneously targeting three viral 
sequences would give extinction in 80% of trials. In order to obtain extinction of 
virus in 100% of trials using molecules of average efficiency, an antiviral strategy 
involving the targeting of four different viral sequences would be required. The 
model showed that the lower the efficiency of individual molecules, the greater 
number of sequences required to be targeted in order to prevent any viral escape 
from occurring. 
 
There are several different methods that have been used to induce coRNAi in the aim 
of reaching the level at which enough viral sequences are targeted at a high enough 
efficiency that no virus is able to escape. These methods can be split into two main 
categories, that of the single transcription unit (STU) (Figure 1.3a) and that of the 
multiple transcription unit (MTU) method (Figure 1.3b). 
 
1.1.3.1 Single transcription unit 
The STU method of coRNAi involves the expression of multiple RNAi inducing 
molecules from a single promoter. Transcription produces a single product, unlike 
the MTU methods that result in multiple products. There are two main STU methods 
that have been investigated, the long hairpin method and the artificial miRNA 





1.1.3.1.1 Long hairpin 
A STU based method that has been looked at is the long hairpin or extended hairpin 
method (Akashi et al., 2005; Liu et al., 2007; Liu et al., 2009b; Saayman et al., 2010; 
Saayman et al., 2008; Watanabe et al., 2006; Weinberg et al., 2007). These hairpins 
are expressed from a RNA pol III promoter and were initially designed with an 
antisense strand composed of a single long target sequence, with mismatches 
introduced into the accompanying sense strand (Akashi et al., 2005; Watanabe et al., 
2006; Weinberg et al., 2007) (referred to as a long hairpin), but further research has 
explored the design of hairpins which contain several individual siRNA duplexes 
(Liu et al., 2007; Liu et al., 2009b; Saayman et al., 2010; Saayman et al., 2008; Sano 
et al., 2008) with the guide sequences on the antisense strand of the hairpin and the 
passenger sequences on the sense strand, and with mismatches incorporated into the 
passenger sequences (referred to as an extended hairpin).  
 
Akashi and colleagues (Akashi et al., 2005) produced a 51 nt long shRNA that 
co-targeted the NS5B gene within two Hepatitis C Virus (HCV) strains differing by 
9 nt. They successfully targeted both gene sequences within individual luciferase 
reporter vectors, and observed that this reduction was induced more rapidly than 
using a standard shRNA method. Following on from this work, Watanabe (Watanabe 
et al., 2006) tested 50 nt and 197 nt long hairpins targeted to the HCV viral gene 
NS2, and observed that both lengths resulted in a reduction in the luciferase 
fluorescence produced by luciferase reporter vectors containing NS2. Weinberg and 
colleagues (Weinberg et al., 2007) tested long hairpins containing 62 nt of a target 






Figure 1.3 Induction methods of combinatorial RNAi 
(a) Single transcription unit method: Two main construct types, (i) the artificial miRNA polycistron or 
„cluster,‟ (ii) the long hairpin. The cluster consists of a single promoter (black arrow) followed by a 
single RNA transcript capable of targeting multiple sequences. The cluster has multiple hairpin 
structures, with flanking sequence between the 3‟ end of the lead hairpin and the 5‟ end of the 
following hairpin. The long hairpin consists of the multiple sense sequences on one strand, followed 
by a loop sequence, and then the antisense sequences on the other strand. (b) Multiple transcription 
unit method: Multiple promoter-hairpin cassettes connected by a string of non-coding nucleotides 
after the promoter termination sequence for each transcript. 
  
Artificial miRNA polycistron Long hairpin
(b) Multiple transcription unit method





sequence at the base of the hairpins were the most highly suppressed and that this 
was likely a result of the higher concentration of siRNAs found to be produced from 
this region of the long hairpin. The results of these studies indicated that multiple 
different siRNAs were being produced from the one precursor hairpin, suggesting 
this could be a useful strategy for targeting gene sequences that differ slightly 
between viral strains and also for preventing viruses from escaping RNAi strategies 
by mutation. 
 
Building on previous research, Liu and colleagues (Liu et al., 2007) further 
investigated STU induction of RNAi using long hairpins that express individually 
functional siRNAs, labelling these „extended hairpins‟. They designed hairpins 
against HIV-1 that express two functional siRNAs that successfully induce sequence-
specific RNAi, and from these extended hairpins determined that the most effective 
positioning of an siRNA within the extended hairpin was at the base (the 3‟ end). 
They also found that a minimal stem length of 43 nt is needed in order to produce 
two effective siRNAs. 
 
Increasing the value of the extended hairpin method as a tool for induction of 
coRNAi, Saayman and colleagues (Saayman et al., 2008) and Liu and colleagues 
(Liu et al., 2009b) used the extended hairpin method to produce three independent 
siRNAs against non-contiguous target sequences. Saayman and colleagues (Saayman 
et al., 2008) tested ~70 nt U6 expressed long hairpins made up of three siRNA 
sequences targeting HIV-1 in alternating orders, and found that the positioning of an 
siRNA at the base of the long hairpin still resulted in the greatest suppressive effect 
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of that siRNA. Liu and colleagues (Liu et al., 2009b) compared extended hairpins 
encoding both three and four siRNA targeted to different HIV-1 genes. They 
observed that a hairpin of three siRNAs at 66 nt in length is optimal for siRNA 
production and suppression of a target, whereas extending the hairpin further 
decreases the hairpins effectiveness. 
 
In an attempt to enable expression of more than three effective siRNAs, Saayman 
and colleagues (Saayman et al., 2010) developed a method that allowed production 
of four effective independent siRNAs against HIV-1. They designed a double 
extended hairpin construct composed of two dual-targeting hairpins of ~50 nt in 
tandem behind a single RNA pol III promoter, connected by a 2 nt UU bridge. They 
were able to detect production of all four siRNAs in the double extended hairpin, and 
verify that each siRNA resulted in suppression of the relevant target. Although the 
suppressive activity of the siRNAs within the construct varied, this method enabled 
expression of four effective siRNAs that could be used to simultaneously target four 
different genes within HIV-1. The suppression produced by the double extended 
hairpin was found to be equal to that produced by an extended hairpin containing 
only two siRNAs, therefore proving this method a useful tool for inducing coRNAi 
and reducing the risk of viral escape. 
 
The advantages of the extended hairpin method are clear, they allow simultaneous 
expression of more than one siRNA while avoiding any disruption to the processing 
of native miRNAs or induction of the interferon response (Liu et al., 2007; Liu et al., 
2009b; Saayman et al., 2010; Weinberg et al., 2007); however there are also 
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limitations to consider. As these hairpins are processed from the stem towards the 
loop this results in a gradient of siRNAs with the highest amount of siRNAs 
produced from the 3‟ end or base of the hairpin, with findings suggesting that three 
effective siRNAs is the limit (Liu et al., 2009a; Liu et al., 2007; Saayman et al., 
2008; Sano et al., 2008; Weinberg et al., 2007). As well as the limit in number of 
siRNAs in an extended hairpin, the efficacy of the siRNAs contained within the 
hairpin varies based on the location within the hairpin and the sequence of the siRNA 
(Lambeth et al., 2010). In order for this method to be used to produce effective 
multiple gene knockdown against a particular target it is important to carefully select 
siRNA sequences and determine the best arrangement of the siRNAs within the 
construct. 
 
1.1.3.1.2 miRNA polycistron mimic 
A second STU based method of inducing RNAi is the creation of an artificial 
miRNA polycistron. Research into creating artificial miRNA polycistrons in order to 
produce multiple RNAi inducing molecules has included both the  mimicking of 
natural polycistrons such as human miR-17-92 (Liu et al., 2008) and human miR-
106b (Aagaard et al., 2008), and also the joining together of artificial pre-miRNAs to 
produce a polycistron like structure (Chung et al., 2006; Snyder et al., 2009; Sun et 
al., 2006; Zhou et al., 2008). Antiviral miRNA polycistrons produced to mimic 
actual miRNA clusters are commonly expressed from a RNA pol II promoter due to 
most primary miRNAs being transcribed by RNA pol II (Lee et al., 2004) and 
because transcription by RNA pol II provides greater control over expression, 
allowing inducible or tissue-specific expression (Chung et al., 2006; Shin et al., 
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2006; Stegmeier et al., 2005); whereas artificial polycistrons produced by joining 
several individual artificial pre-miRNAs have been expressed from both RNA pol 
type II and type III promoters. 
 
Liu and colleagues (Liu et al., 2008) used the RNA pol II Human Cytomegalovirus 
Immediate-Early promoter to express artificial polycistrons based on the human 
miR-17-92 cluster. The cluster contains six pre-miRNAs and produces seven mature 
miRNAs, as miR-17 produces one mature miRNA from each strand. Constructs were 
designed using the first five pri-miRNA structures with a single mature siRNA 
sequence placed on the 5‟ arm of the miR-17 pre-miRNA. The native miRNA 
sequences were exchanged for antiviral siRNA sequences targeted to five different 
HIV-1 genes, with mismatches introduced into the passenger strands to better mimic 
the pre-miRNAs. The artificial pre-miRNAs were then joined together to produce 
different combinations of two, three and four antiviral miRNAs; and expression of an 
antiviral miRNA as part of a polycistron was found to increase the suppressive effect 
of the hairpin. Suppression of HIV-1 replication was found to be increased in cells 
stably expressing a polycistron of four different siRNAs compared to cells 
expressing any of the individual antiviral miRNAs that were used to produce the 
polycistron, showing that artificial polycistrons can be used effectively to target 
several viral genes simultaneously. 
 
Another miRNA polycistron that has been used for expression of multiple antiviral 
molecules is the miR-106b cluster that contains the three miRNAs miR-106b, 
miR-93, and miR-25. Aagaard and colleagues (Aagaard et al., 2008) cloned the 
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cluster behind a RNA pol II Human Cytomegalovirus Immediate-Early promoter and 
modified it to contain three siRNAs targeting different HIV-1 genes, with 
mismatches introduced into the passenger strands. They determined that the 
pri-miRNA flanking sequences were very important to siRNA functionality, with 
their removal resulting in the abolishment of suppressive activity. 
 
In 2006 Das and colleagues (Das et al., 2006) produced an antiviral polycistron 
based on the section of the miR-106a cluster that includes miR-19b-2 and miR-92-2 
expressed from a chicken RNA pol III U6 promoter. They cloned the section of the 
cluster and inserted artificial pre-miRNAs that contained the base of the stem and 
loop sequence of miR-30 but had gene specific target sequences. This construct was 
found to result in effective suppression of each of the two target genes to a level 
equivalent to that produced by vectors containing the antiviral pre-miRNAs 
individually. 
 
The joining or chaining together of individual artificial pre-miRNAs has been 
researched by a number of groups, with many of the artificial pre-miRNAs modelled 
on miR-30 (Snyder et al., 2009; Sun et al., 2006), and also on miR-155 (Chung et al., 
2006). Sun and colleagues (2006) suppressed two genes simultaneously using two 
linked artificial miR-30 hairpins modified to contain siRNAs and expressed from a 
RNA pol II Human Cytomegalovirus Immediate-Early promoter. In support of 
previous findings (Liu et al., 2008) Sun et al. (2006) found that the joining of an 
individual hairpin with a second hairpin improved the suppressive activity of the first 
hairpin. This occurred although the second hairpin was not targeted to the same gene, 
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indicating it occurred as a result of linking the hairpins. The increase in suppressive 
activity was shown to be a result of an increase in mature siRNA levels suggesting 
that the chaining of the first hairpin to the second has an effect on processing 
efficiency.  
 
Following on from the previous research carried out in the field, Snyder et al. (2009) 
compared clusters containing two and four artificial pre-miRNAs based on miR-30 
expressed from a RNA pol III promoter. Rather than observing an increase in 
suppressive activity of the constructs by increasing the number of artificial 
pre-miRNAs, they observed a decrease. As the suppressive activity of the plasmids 
was shown to increase with promoter strength and with higher dose, it was surmised 
that this result was likely due to issues with the transcription, folding, or processing 
of the longer four artificial pre-miRNA transcript; rather than saturation of 
processing pathways. Therefore, although linking artificial pre-miRNAs together can 
improve suppressive activity even when the second linked hairpin is irrelevant, this 
indicates that there is an upper limit at which adding more hairpins to the polycistron 
decreases its overall effectiveness. 
 
In order to enable the design of optimum constructs the exploitation of miRNA 
polycistrons for antiviral RNAi requires further understanding. This method has 
potential to produce strong coRNAi while minimising the risk of a negative impact 
on the cell, and therefore could be a method of induction suitable for a downstream 




1.1.3.2 Multiple transcription unit 
One strategy of inducing coRNAi is via the use of MTUs, these constructs contain 
multiple expression cassettes made up of a promoter and an RNAi inducing molecule 
such as shRNA or artificial pre-miRNA, and transcription results in the production of 
individual hairpins. A range of lengths of MTUs have been produced, varying from 
two to six promoter-shRNA cassettes (Anderson and Akkina, 2005; Brake et al., 
2008; Cheng et al., 2009; Gonzalez et al., 2005; Gou et al., 2007; Henry et al., 2006; 
Hinton and Doran, 2008; Lambeth et al., 2010; McIntyre et al., 2011a; Song et al., 
2008). MTUs can be used to induce degradation of multiple targets, whether all 
targets are within a virus, or some within a virus and some within host encoded 
co-factors (Eekels et al., 2011); or to increase the strength of RNAi against a single 
target by targeting the same sequence repeatedly (Gonzalez et al., 2005).  
 
Although research has been performed into the development of a cloning strategy 
that enables production of MTU constructs with an infinite number of promoter-
shRNA cassettes (McIntyre et al., 2008), limitations in the processing efficiency and 
suppressive activity of the molecules within a construct, along with the risk of 
causing toxicity to the cell by expressing large amounts of exogenous RNA; restrict 
the number of cassettes plausible in a MTU construct. McIntyre et al. (2011a) tested 
MTU constructs containing from one to four cassettes and found that MTU 
constructs can be effectively used to express up to four promoter-shRNA cassettes; 
Lambeth et al. (2010) determined that five shRNA cassettes could be expressed 





Studies have found that simultaneously expressing multiple hairpins, whether by 
co-transfection of the individual shRNAs or by combining shRNAs in a MTU 
construct, can cause a reduction in the individual suppressive activity of the hairpins 
(Hinton and Doran, 2008; McIntyre et al., 2011a; Schopman et al., 2011) and this 
finding has been attributed to competition of the hairpins produced for access to 
components of the RNAi pathway. Hinton & Doran (2008) found that the 
suppressive effect of a three cassette MTU was reduced compared to that produced 
by the most efficient shRNA alone, and that this reduced suppression was equal to 
that produced by co-transfection of the individual hairpins contained in the MTU. 
McIntyre and colleagues (2011a) found that simultaneously expressing multiple 
hairpins from an MTU resulted in a reduction in the individual suppressive activity 
of the incorporated hairpins in direct relationship with increasing the number of 
hairpins. Hairpin competition has been  previously investigated and it has been 
determined that the majority of competition is likely to occur at the level of 
incorporation of the siRNA duplexes into RISC, but that there may also be 
competition for the Exportin-5 pathway (Castanotto et al., 2007; O'Brien, 2007). 
 
Along with investigating the individual suppressive activity of the hairpins within an 
MTU construct, McIntyre et al. (2011a) looked at the net suppressive activity of a 
MTU construct against a single target such as a virus. They found that a construct 
containing only highly active hairpins resulted in suppression at an equivalent level 
to that of the individual hairpins combined. Although the same question was not 
answered when using one or more poorly active hairpins it was hypothesised that this 
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would likely result in a decrease in the net activity, as the poorly active hairpin 
would be competing with the more highly active hairpins and inhibiting the amount 
that progressed through the RNAi pathway to result in suppression of the target. 
Therefore, it is important to use only highly active hairpins in a MTU. 
 
In order to better prevent the development of resistant strains as a result of viral 
escape, Schopman et al. (2010) tested a slightly different approach. They developed 
a MTU strategy based on knowledge gained from their previous research (von Eije et 
al., 2008), producing two 2
nd
 generation shRNAs targeting mutated sequences they 
had found to be most commonly used for viral escape. These 2
nd
 generation shRNAs 
were incorporated into a MTU also containing a shRNA targeted to a highly 
conserved sequence in the original virus that was found to produce a highly restricted 
escape profile. The results showed that the MTU actually produced a decreased level 
of inhibition compared to the individual 1
st
 generation shRNA, and this was surmised 
to be due to hairpin competition. As the two 2
nd
 generation shRNAs only target the 
mutated virus they would not add to the suppressive effect of the 1
st
 generation 
shRNA, but would still compete with it for access to RISC, therefore reducing its 
suppressive activity. This research found that it is best to continue to develop 
coRNAi strategies incorporating highly potent shRNAs against multiple targets in 
the non-mutated virus, resulting in higher suppression of virus production and 
preventing viral escape due to the number of targets the virus would have to acquire 




As well as the studies that have found evidence of hairpin competition there have 
been those that have not (Henry et al., 2006; Lambeth et al., 2010). Lambeth and 
colleagues (2010) found that the level of suppression produced by individual 
shRNAs within the MTU constructs was independent of the number of cassettes 
within a construct, with shRNAs within a five cassette construct producing 
suppression equal to that of the relevant individual shRNA vector.  
 
Leonard and Schaffer (2005) predicted that four molecules of average efficiency 
targeting four individual conserved sequences within HIV-1 would be sufficient to 
result in extinction of virus 100% of the time, and coRNAi strategies using the MTU 
construct design have been developed which are able to express up to six shRNA 
molecules. Therefore it is plausible that any known highly mutating virus could be 
successfully suppressed by the careful selection of shRNA molecules and the 
optimisation of the resulting MTU constructs. 
 
In order to investigate the optimisation of methods used to induce RNA interference 
a virus model is needed. The work within this study focused on targeting conserved 
sequences within influenza A viruses. A potential downstream application of 
effective MTU constructs would be the incorporation of constructs into an antiviral 
strategy involving the production of transgenic chickens with resistance to influenza 




1.2 Avian influenza 
Since the first isolation of AI in 1996 from a farmed goose in China, there have been 
334 human fatalities out of 569 cases (WHO, 2011), giving AI a case fatality rate of 
more than 50%. Although human to human transmission has not yet been observed, 
there is great fear of AI reaching pandemic levels due to the high rate of mutation 
exhibited by most influenza viruses, as a result of the error prone RNA polymerase 
(Parvin et al., 1986). If a human was co-infected by both a human influenza and AI 
virus, antigenic shift could result in a re-assorted AI virus capable of being passed 
from human to human. It is also possible that slight amino acid substitutions in avian 
haemagglutinin as a result of mutation may result in AI being able to be transferred 
from human to human (Frank, 2002). 
  
Due to the high mutation rate of influenza viruses, escape mutants that are resistant 
to current vaccine strategies are continually developing. One method being looked at 
for future protection from viruses is coRNAi, with the potential to target more than 
one sequence within a virus simultaneously showing great promise at preventing 
development of resistant strains. In order to determine the best targets within the 
virus it is important to have a greater understanding of the virus genome. 
 
1.2.1 Virus genome 
Influenza viruses are members of the orthomyxoviridae family, and are divided into 
three genera, influenza A, B, or C, according to the antigenic differences among their 
nucleoprotein (NP) and matrix proteins. Influenza A viruses are able to infect both 
avian and mammalian hosts, whereas B and C viruses are limited to human hosts. 
 28 
  
Viruses classed as influenza A are further divided into subtypes depending on the 
antigenic relationships of their haemagglutinin and neuraminidase (NA) surface 
glycoproteins, with a total of 16 different HA and 9 different NA subtypes having 
been identified so far (Fouchier et al., 2005). 
 
Influenza has a segmented genome of eight single-stranded, negative sense RNA 
molecules that produce ten proteins: three polymerase subunits (PB1, PB2, and PA), 
haemagglutinin, NP, matrix proteins (M1, M2), neuraminidase (NA), and the 
non-structural proteins (NS1 and NS2) (Figure 1.4). On the outside of the influenza 
viral envelope there are projections of rod-shaped trimers of HA and mushroom- 
shaped tetramers of NA, that act as the main targets for neutralising antibodies in a 
protective immune response, and are the least conserved of all the viral genes among 
influenza A subtypes (Obenauer et al., 2006). The HA protein allows the virion to 
attach to a host cell so that it can infect it. 
 
The genome and polymerase complex lay within the virus particle. The polymerase 
complex is made up of the three viral polymerases, PB1, PB2, and PA, along with 
NP, and enables transcription of the negative-sense viral RNA into plus-sense 
mRNA so that viral replication can be initiated. Both nucleoprotein and the 
polymerase subunits are highly conserved across influenza A strains (Altmuller et 
al., 1989; Obenauer et al., 2006) and therefore provide good targets for RNAi. The 









Figure 1.4 Influenza genomic organisation 
Influenza is a single-stranded, negative sense RNA virus with a segmented genome. Extruding from 
the viral envelope are the neuraminidase (NA) and haemagglutinin (HA) proteins, haemagglutinin 
allows the virus to attach to a host cell prior to initiating infection. On the inside of the virion are the 
three polymerase subunits PB1, PB2, and PA; the non-structural proteins (NS1 and NS2), the matrix 


















RNAi can be a highly effective technique for the suppression of virus production. 
However, the high mutation rate of viruses such as influenza allows escape from 
RNAi strategies targeting only a single sequence, due to the high sequence 
specificity of RNAi. Therefore a strategy where multiple sequences are targeted is 
required. 
 
In order to obtain a successful coRNAi strategy it is important to carefully select the 
molecules that will be incorporated into the construct and also the type of construct 
that will be used to express these molecules. In this study shRNA molecules known 
to be effective against AI were optimised by the incorporation of a pre-miRNA 
derived loop in place of the widely used artificial loop (Brummelkamp et al., 2002). 
The pre-miRNA loop found to most consistently produce improved processing 
efficiency was then used for shRNAs incorporated into MTU constructs termed 
MWHs. The MWH constructs were designed such that their analysis enabled 
investigation of the factors that affect processing and suppressive ability of the 
shRNAs within them. 
 
This study aims to further the knowledge of the use of RNAi for the targeting of 
genes in the context of creating antiviral transgenes capable of simultaneously 
targeting multiple viral genes and therefore preventing the risk of viral escape. 
Research performed in this study has investigated the optimisation of individual 
shRNAs as well as the use of a MTU method of inducing coRNAi.   
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CHAPTER 2. Materials and Methods 
2.1 Nucleic acid sequence data 
Sequences for miRNAs in this thesis were sourced from miRBase release 18 
(November 2011) (http://www.mirbase.org) and sequences for influenza genes were 
sourced from the National Centre for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov).  
 
2.2 General data analysis 
Graphs and statistical analyses were performed using Prism5 software (v5.03, 
GraphPad Software Inc, 2009). Comparisons between samples were performed using 
a one-way analysis of variance (ANOVA) with the Tukey‟s post-hoc test unless 
stated otherwise. Other tests performed were unpaired two-tailed t-tests. 
 
2.3 Image analysis 
All raw images were saved in Tagged Image File Format format. Figures were 
produced using Microsoft Powerpoint 2007 (Microsoft Corporation). 
 
2.4 Primers, probes and oligonucleotides 
A table of all primers and oligonucleotide probes used in this study is included in 
Appendix A. Polymerase chain reaction (PCR) primers were designed using Clone 
Manager 9.0 software (SciEd Central) and obtained from Geneworks (Australia). 
PCR primers were designed obeying the following rules: 18-24 nt length, 40-60% 
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GC content, 50-65°C melting temperature, 1-2 nt GC clamp, maximum 
polynucleotide repeats (N) = 4. 
 
All primers were received as lyophilised DNA and were re-suspended in tissue 
culture grade water (tcH2O) to a stock concentration of 100 µM. Working primer 
stocks were prepared at 5 µM for quantitative reverse transcriptase PCR (qRT-PCR) 
(Section 2.14). One step PCR primers used for construction of miRloop shRNAs 
(Section 2.5.3) and the MWH constructs (Section 2.5.4) were constructed with 
additional High Performance Liquid Chromatography purification. Locked nucleic 
acid (LNA) probes were obtained unlabelled from Sigma-Aldrich (USA). 
 
2.5 Plasmids 
2.5.1 EGFP-fusion plasmid construction 
Enhanced green fluorescent protein (EGFP) fusion plasmids contain the EGFP gene 
and a segment of the targeted influenza gene. Transcription of these plasmids 
produces a single transcript containing EGFP and the gene segment, therefore 
successful targeting of the influenza gene segment results in a decrease in EGFP 
fluorescence. This gives an indication of the ability of a shRNA to suppress a gene. 
 
The pEGFP-NP, pEGFP-PB, and pEGFP-PA plasmids used for preliminary testing 
of RNAi inducing molecules were a generous gift from T. Wise CSIRO, Australia. 
The pEGFP-NP, pEGFP-PB, and pEGFP-PA plasmids contain a 200-600 nt segment 
of the NP, PB, or PA influenza A gene sequences respectively. The partial gene 
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sequences were cloned into pEGFP-C (a generous gift from Dr David Cummins, 
CSIRO-LI, Australia).  
 
2.5.2 shRNA plasmid construction 
Chemically synthesised siRNAs targeting highly conserved sequences of influenza A 
genes have previously been used to produce dramatic inhibition of H1N1 virus 
growth (A/PR/8/34 (PR8) and A/WSN/33 (WSN) influenza A strains) (Ge et al., 
2003). Some of these siRNA sequences were selected for incorporation into shRNAs. 
These shRNAs contain a 9 nt loop sequence (Brummelkamp et al., 2002), and are 
expressed from a plasmid system utilising chicken U6 promoter 4 (chU6-4 GenBank 
accession no. DQ531570) (Kudo and Sutou, 2005; Wise et al., 2007). These 
molecules were kindly provided by T.Wise and will be referred to as shNP-1496, 
shNP-1498, and shPB1-2257. The shPB1-2257 molecule targets the PB1 gene, 
whereas shNP-1496 and shNP-1498 (T. Wise, unpublished data) target the NP gene. 
All siRNA sequences used in this study are 100% conserved in the H1N1 and H5N1 
virus strains used for analysis of suppressive activity. 
 
The pCluckshEGFP plasmid (shEGFP) encoding a shRNA containing the EGFP 
siRNA sequence from Kim and Rossi (Kim and Rossi, 2003) was kindly provided by 
T. Wise for use as an irrelevant control in the H1N1 suppression experiments.  
 
2.5.3 miRloop shRNA plasmid construction 
Additional PB1-2257 and NP-1496 targeting shRNAs were designed to contain 
identical siRNA sequences to those previously mentioned, but with a loop sequence 
 34 
  
taken from a chicken pre-miRNA in place of the 9 nt loop sequence. Chicken, gallus 
gallus (gga), pre-miRNA sequences were obtained from miRBase 
(http://www.mirbase.org/): gga-miR-122-1 (miR-122) (miRBase ref: MI0001277), 
gga-miR-107 (miR-107) (miRBase ref: MI0001215), and gga-miR-19b (miR-19b) 
(miRBase ref: MI0001180). Loop sequences were defined as the entire region that 
separates the sense strand of the predicted mature miRNA from the antisense strand 
in the pre-miRNA hairpin. For convenience purposes within this thesis the 
terminology of 5‟ strand and 3‟ strand will be used to refer to the sequence within the 
pre-miRNA that is 5‟ of the loop and the sequence that is 3‟ of the loop respectively. 
Two miR-122 loop shRNAs were designed for each of the siRNA sequences, one 
with the desired mature siRNA sequence on the 5‟ strand, and one with it on the 3‟ 
strand. The miRloop shRNA expression constructs produced were named 
NPmiR122-5‟, NPmiR122-3‟, NPmiR107, NPmiR19b, PBmiR122-5‟, PBmiR122-
3‟, PBmiR107, and PBmiR19b.  
 
One-step PCR primers were used to produce a PCR product containing the shRNA 
behind the RNA pol III type III U6-4 promoter by using a plasmid containing the 
chU6-4 promoter as the template DNA. A universal forward primer (TD175 or 
TD233) containing the first 20 nt of the chU6-4 promoter was paired with a reverse 
primer containing the last 20 nt of the chU6-4 promoter, and hairpin sequence 
containing loop, terminator sequence, and a XhoI site to enable easy restriction digest 
identification of full length PCR fragments. The universal forward primer TD233 
used for construction of the miRloop shRNAs, contained a SalI site in front of the 
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chU6-4 sequence. The primers used are shown in Appendix A and were obtained 
from Geneworks (Australia).  
 
PCR was performed using Platinum PCR Supermix (Invitrogen, USA) and products 
were cloned into the pGEM-T Easy Vector (Promega, USA) as per manufacturer‟s 
instruction. The PCR cycle settings used were as follows: an initial activation step of 
94°C 2 minutes, 35 cycles of  denaturation (94°C 30 seconds), annealing (55°C 30 
seconds) and extension (72°C 1 minute), and a final extension step of 72°C  1 
minute. 
 
2.5.4 Multiwarhead plasmid construction 
Plasmids containing multiple influenza targeting shRNAs containing the miR-107 
loop were constructed by first producing the three individual promoter-shRNA 
transcription units that the MWH plasmids are composed of: chU64-PB1, chU63-NP, 
chU61-PA. The siRNA sequences PB1-2257, NP-1496, and PA-2087 were selected 
from a previous study which tested chemically synthesised siRNAs  targeting highly 
conserved sequences of influenza A genes against H1N1 virus (PR8 and WSN 
influenza A strains) (Ge et al., 2003). 
 
The units were each constructed by one-step PCR using a forward primer containing 
18-20 nt of the 5‟ end of the promoter sequence, and a reverse primer containing the 
antisense strand of the shRNA, the miR-107 derived loop sequence, the sense strand, 
and 18-20 nt of the 3‟ end of the promoter sequence. See Appendix A for primer 
sequences. The plasmids used as templates for the promoter sequences of 
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chU64-PB1, chU63-NP, chU61-PA were pCluckshEGFP, pU63-NP1, and p3P-100. 
The plasmids pU63-NP1 and p3P-100 were kindly provided by Kirsten Morris and 
Dr Tracey Hinton respectively (CSIRO, Australia). The PCR products contain a 
chicken pol III U6 promoter and shRNA components (sense, loop, antisense and 
terminator sequences). The three transcription units were ligated together using the 
compatible SalI and XhoI sites on the 5‟ and 3‟ ends of the PCR products, in order to 
produce the four different MWH plasmids.  
 
2.6 General molecular biology techniques 
2.6.1 DNA sequencing 
All sequencing was performed by the Micromon DNA Sequencing Facility (Monash 
University, Australia). Sequencing of the shRNA expression plasmids  was 
performed using the universal primers prepared and provided by the Micromon DNA 
sequencing facility- M13 forward (5‟-GTAAAACGACGGCCAGT-3‟) and reverse 
(5‟- AACAGCTATGACCATG-3‟). 
 
2.6.2 Bacterial strains, media and growth 
The plasmids produced for this project were cloned in electrocompetent Escherichia 
coli (E. coli) strain Top10F‟ (Invitrogen), bacterial cells were grown in Luria Bertani 
(LB) broth with 100 µg/mL antibiotic (specific to the vector), or on LB agar plates 
containing 100 µg/mL of the relevant antibiotic. Liquid bacterial cell cultures were 
grown overnight (12-16 hours) at 37°C with shaking (300 revolutions per minute) in 





2.6.3 Transformation of plasmid DNA into E. coli 
Electroporation was used to transform pre-prepared electrocompetent E. coli cells 
(Invitrogen) with plasmid DNA or ligations. Cells stored in 40 μl aliquots were 
thawed and placed immediately on ice, mixed with 2 μl ligation reaction or plasmid 
DNA, and added to cold 0.2 cm cuvettes (BioRad, USA). A Gene Pulser 
transformation apparatus (BioRad) set to 25 μF, 2.25 V and 200 Ω was used to 
electroporate the E. coli cells. Immediately after electroporation 1 mL room 
temperature LB broth was added to the transformation mixture, and this solution was 
transferred into a 5 mL centrifuge tube (Falcon tube, BD Biosciences, USA) and 
incubated for 1 hour with shaking at 37°C. Aliquots of 500 μl were spread onto LB 
agar plates plus the relevant antibiotic, and incubated at 37°C overnight. 
 
2.6.4  Plasmid DNA purification from E. coli cultures 
2.6.4.1 Small-scale plasmid isolation 
Small-scale isolation of plasmid DNA from transformed E. coli was conducted using 
the QIAprep Spin Miniprep Kit (Qiagen, Germany) which was developed from the 
method published by Birnboim & Doly (Birnboim and Doly, 1979). Isolation was 
performed according to the manufacturer‟s instructions. Briefly, single bacterial 
colonies growing on LB agar plates containing 100 µg/mL antibiotic were picked 
using sterile wooden toothpicks and inoculated into 5 mL LB broth (containing 100 
µg/mL antibiotic). Cultures were grown overnight (Section 2.6.2), and 1.5 mL 
aliquots transferred to 1.5 mL microcentrifuge tubes and centrifuged at 17,900 g for 
1 minute in order to pellet the bacterial cells, and the supernatants discarded. After 
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resuspension, lysis, neutralisation and precipitation of protein according to the 
manufacturer‟s protocol, the DNA supernatants were transferred to spin columns 
(QIAprep, Qiagen), and centrifuged at 17,900 g for 1 minute to bind the DNA to the 
column membrane. The membranes were washed with 500 µl buffer PB and then 
750 µl buffer PE, and a final 1 minute 17,900 g centrifugation was performed to 
remove residual ethanol from the spin column membranes. Purified plasmid DNA 
was eluted in 50 µl buffer EB or tcH2O and stored at -20°C. Plasmids were digested 
(Section 2.6.6) and those with the correct restriction digest pattern were sequenced 
(Section 2.6.1) to ensure they were correct. 
 
2.6.4.2 Large-scale plasmid isolation 
Transformed E. coli was grown by inoculating 200 mL LB broth (containing 100 
µg/mL antibiotic) with a 100 µl aliquot of bacterial culture containing the required 
plasmid, and leaving the culture to grow overnight (Section 2.6.2). Large-scale 
isolation of plasmid DNA was carried out using the Pureyield Plasmid Maxiprep 
System (Promega) which was developed from the method published by Birnboim & 
Doly (1979).  
 
Isolation was performed according to the manufacturer‟s instructions. Briefly, the 
200 mL bacterial broths were transferred to autoclaved 250 mL centrifuge bottles 
(Beckman Coulter, USA) and subjected to centrifugation (Avanti J-25 I, Beckman 
Coulter) at 5,000 g for 10 minutes at 20°C. Supernatant was discarded, and following 
resuspension, lysis and protein precipitation, a second centrifugation was performed 
at 14,000 g for 20 minutes at 20°C. The lysate (supernatant) was decanted into the 
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assembled column stack (the clearing column on top of the binding column) and 
vacuum suction applied until the lysate passed through both columns, the clearing 
column was removed, and the DNA on the binding column was washed by applying 
5 mL Endotoxin Removal Wash followed by 20 mL Column Wash.  
 
The membrane was dried by applying vacuum for 5 minutes, after which the binding 
column was removed from the vacuum scaffold and placed in a disposable 50 mL 
centrifuge tube (Falcon tube, BD Biosciences). DNA was eluted by applying 1.5 mL 
tcH2O to the binding column and centrifuging at 2,000 g for 5 minutes in a swinging 
bucket rotor (Rotina 48R, HD Scientific suppliers, Australia). Eluted DNA was 
transferred to a 1.5 mL microcentrifuge tube and stored at -20°C. 
 
2.6.5 Measurement of nucleic acid concentrations 
DNA and RNA sample concentrations were determined using a spectrophotometer 
(NanoDrop ND-1000 3.3 Spectrophotometer, NanoDrop Technologies, USA), 
coupled to a computer (Optiplex GX280, Dell, USA). Nucleic acid samples were 
measured in 1 μl aliquots and concentrations were reported for DNA and small RNA 
samples against extinction coefficients (ε) of 50 and 33, respectively.  
 
2.6.6 Restriction endonuclease digests 
All restriction enzymes used in this study were obtained from Promega. Double 
digest reactions undertaken for cloning were carried out using 10 U of each enzyme, 
5 μl 10x buffer (specific to the enzyme), 5 μl 10x bovine serum albumin (BSA) (if 
required), 100-500 ng plasmid DNA, and tcH2O to a final reaction volume of 50 µl. 
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Double digest reactions undertaken to screen for correct plasmids were carried out 
using 2 U of each enzyme, 2 μl 10x buffer, 2 μl 10x BSA, 40-200 ng plasmid DNA, 
and tcH2O to a final reaction volume of 20 μl. All reactions were incubated at 37°C 
for 2 hours prior to analysis of products using agarose gel electrophoresis (Section 
2.6.7). 
 
2.6.7 Separation of nucleic acids by agarose gel electrophoresis 
DNA samples to be analysed or purified using gel electrophoresis were separated 
using 1 % (w/v) agarose gels produced by dissolving 1 g DNA grade agarose 
(ProBioGen, Germany) per 100 mL 1x TAE buffer (40 nM Tris (pH 8.0), 20 mM 
acetic acid, 1 mM ethylenediaminetetraacetate acid (EDTA), and GelRed 
(Biotium, USA)  (1:10000).  
 
DNA samples were prepared by mixing with 6x DNA loading dye (1:10) (Fermentas, 
Canada), and separated for 30-60 minutes at 100 V. Double stranded DNA markers 
were prepared using 20 μl 1 kb plus DNA Ladder (Invitrogen), 33 μl 6x loading dye 
and 47 μl tcH2O, and 4 μl was run alongside DNA samples to allow size estimation 
of the separated products. Gels were viewed using a transilluminator (UVP 
White/UV-transilluminator) and images captured (UVPgrab Grab-IT annotating 
grabber 2.04.07 Software. UVP Inc, USA).    
 
2.6.8 Purification of DNA gel fragments and PCR products 
DNA fragments excised from agarose gels, and PCR reaction mixtures, were purified 
according to the manufacturer‟s protocol (Wizard SV Gel and PCR Clean-Up 
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System, Promega). Briefly, the gel pieces were dissolved in an equal volume of 
Membrane Binding Solution at 65°C for 10 minutes, mixed and applied to an SV 
Minicolumn placed in a 2 mL collection tube, and centrifuged at 16,000 g using a 
microcentrifuge (Biofuge pico, Heraeus Instruments, Germany). For PCR reaction 
mixtures an equal volume of Membrane Binding Solution was added, mixed and then 
processed identically to the dissolved gel pieces. Membrane Washing Solution was 
applied to the Minicolumn and the assembly again centrifuged at 16,000 g. Purified 
DNA was eluted from the spin-column using 30-50 μl tcH2O, and stored at -20°C.  
 
2.7 Cells and virus 
Chicken fibroblast cells (DF1: ATCC No. CRL-12203) were grown in Dulbecco‟s 
Modified Essential Medium (DMEM) (bicarbonate free) supplemented with 10% 
(v/v) foetal bovine serum, 2 mM glutamine, 10 mM N-2-hydroxyethylpiperazine-N‟-
2-ethanesulfonic acid (HEPES), 1.5 g/l sodium bicarbonate, 0.01% (w/v) penicillin 
and 0.01% (w/v) streptomycin. Madin Darby canine kidney cells (MDCK: ATCC 
No. CCL-34) were grown in Eagle‟s Modified Essential Medium (EMEM) 
supplemented with 10% (v/v) foetal bovine serum, 2 mM glutamine, 10 mM HEPES,  
0.01% (w/v) penicillin and 0.01% (w/v) streptomycin. Green monkey kidney cells 
(Vero: ATCC No. CCL-81) were grown in EMEM supplemented with 10% foetal 
bovine serum, 2 mM glutamine, 10 mM HEPES,  1.5 g/l sodium bicarbonate,  0.01% 
(w/v) penicillin and 0.01% (w/v) streptomycin. All cell lines used were grown at 




Production of H1N1 influenza strain PR8 virus stock was performed by limiting 
dilution passage in the allantoic cavity of ten day old embyronated chicken eggs at 
37°C for 48-72 hours. 
 
2.8 Transfection protocols 
2.8.1 Chemical transfection of plasmid DNA  
DF1 cells were seeded at 1.5x10
5
 cells in 24-well tissue culture plates (Nunc, 
Denmark) in duplicate and grown overnight at 37°C with 5% (v/v) CO2. 
Lipofectamine 2000 (Invitrogen) was used to transfect cells with plasmids, following 
manufacturer‟s instructions. Briefly, 500 ng of pEGFP-NP or pEGFP-PB, and 500 ng 
of the relevant shRNA plasmid was diluted in 50 µL OptiMEM (Invitrogen) before 
being mixed with 50 µL of OptiMEM containing 2 µL of Lipofectamine 2000. These 
DNA: Lipofectamine mixes were incubated at room temperature for 20 minutes 
before being added to cells and incubated overnight at 37°C with 5% (v/v) CO2. The 
transfection media was replaced with fresh cell growth media, and cells were 
incubated for a further 72 hours before being prepared for analysis by flow cytometry 
(Section 2.9). 
 
Transfection of cells for extraction of RNA to be analysed by Northern blotting were 
performed as follows. Adherent cells were seeded in 25cm
2
 tissue culture flasks 
(Corning) at a density of 5 x 10
6
 cells and grown at 37°C with 5% (v/v) CO2 for 24 
hours. Lipofectamine 2000 (Invitrogen) was used to transfect cells following the 
protocol described previously, with the following differences. For a single 
transfection 12.5 µg of plasmid DNA was used; for a co-transfection 12.5 µg of each 
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of the two plasmids were used. The Lipofectamine-OptiMEM mix was prepared at 
20 µL Lipofectamine 2000 in 500 µL OptiMEM per flask. Plasmid DNA was diluted 
in 500 µL OptiMEM. 
 
Transfection of cells for extraction of RNA to be analysed by RNase Protection 
Assay (RPA) were performed as follows. Adherent cells were seeded in six well 
plates (Nunc, Denmark) at a density of 5 x 10
5
 cells and grown at 37°C with 5% 
(v/v) CO2 for 24 hours. Lipofectamine 2000 (Invitrogen) was used to transfect cells 
following the protocol described above, with the following differences. For a single 
plasmid transfection 3 µg plasmid DNA was used; for a co-transfection 3 µg of each 
of the two plasmids were used. The Lipofectamine-OptiMEM mix was prepared at 
10 µL Lipofectamine 2000 in 250 µL OptiMEM per well. Plasmid DNA was diluted 
in 250 µL OptiMEM. 
 
2.8.2 Mammalian cell electroporation of plasmid DNA 
Electroporation of MDCK cells in order to transfect them with plasmid DNA was 
performed using a Invitrogen Neon™ Transfection System (Invitrogen) using the 
100 µL tips, following manufacturer‟s instructions. After seeding a 75cm2 tissue 
culture flask (Corning) with MDCK cells and incubating the flask at 37°C with 5% 
(v/v) CO2 until cells formed a confluent monolayer, cells were treated with 5 mL 
trypsin versene (GIBCO, USA) to remove them from the flasks surface, and 
resuspended in cell media. Aliquots of 1.5 x 10
6
 cells were pelleted by centrifugation 
at 10,000 g for 3 minutes, the cell media removed, the pellet resuspended in 
phosphate buffered saline A (PBSA), and again pelleted by centrifugation at 10,000 
 44 
  
g for 3 minutes. The PBSA was removed and the cells were resuspended in 100 µL 
Resuspension Buffer R, and mixed with 2.5 µg of the plasmid DNA to be 
transfected. This solution was electroporated using program MDCK16 with the 
parameters of Pulse voltage 1400 v, Pulse width 20 ms, Pulse number 2. The 
electroporated cells were immediately aliquoted into 2.9 mL pre-warmed MDCK 
growth media (37°C), and 450 µL was aliquoted into 6 wells of a 24-well culture 
plate (Nunc, Denmark) and incubated overnight at 37°C with 5% (v/v) CO2.  
 
2.8.3 Influenza infections 
H1N1 influenza PR8 virus was serially diluted in viral growth media (0.3% (v/v) 
BSA, 2 µg/mL TPCK-Trypsin (Sigma-Aldrich) and no foetal calf serum (FCS)) and 
duplicate cell samples were infected at different multiplicities of infection (MOI) 
ranging from 0.001 to 1. Cells were incubated with virus for 1 hour at 37°C before 
the virus containing media was replaced with fresh viral growth media and incubated 
for 48 hours.  
 
Supernatants were used in haemagglutination (HA) assays according to the OIE 
manual. Briefly, serial two-fold dilutions of virus in PBS were mixed in with an 
equal volume of a 0.5% (v/v) chicken erythrocyte suspension. After incubation at 
room temperature for 1 hour the HA titer of both duplicates of each transfected 
sample was estimated by the highest dilution where haemagglutination was observed.  
 
Dilutions of the virus supernatants from the shRNA treated cells were performed as 
follows in order to allow calculation of the TCID50 of the supernatants. MDCK cells 
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were seeded at 10,000 cells per well and grown overnight at 37°C with 5% (v/v) 
CO2. Virus supernatants taken from cell samples infected with virus at a MOI of 0.1 
and frozen down at -80°C were thawed on ice and a 96 well U bottom plate (Nunc, 
Denmark) was used to perform serial 10-fold dilutions (down to 10
⁻8
) with each 
sample. Virus dilutions were then added onto the monolayers of MDCK cells in 
replicates of 10. The infected cell cultures were checked for cytopathic effects (CPE) 
daily over a period of 7 days and the cell samples displaying CPE were recorded at 
day 5 and day 7. The TCID50/mL of each virus supernatant was then calculated using 
the Reed-Muench (Reed and Muench, 1938) method. 
 
2.9 Flow cytometry 
Flow cytometry was carried out on duplicate samples of transfected DF1 and Vero 
cells at 72 hours post transfection. Cell monolayers were washed with PBSA, 
trypsinized, pelleted by centrifugation, washed in PBSA, resuspended in 200 μL of 
1% (v/v) FCS in PBSA and analysed using a LSR II flow cytometer (Becton 
Dickinson). Data analysis was performed using CELLQuest software (Becton 
Dickinson) and mean fluorescence intensity (MFI) values were obtained. Average 
MFIs for each transfection condition were calculated from duplicate MFI values 
(Microsoft Excel software, Microsoft). The fluorescence produced by the relevant 
EGFP-fusion plasmid alone (negative control) was allocated 100% and the 
fluorescence produced by cell samples co-transfected with the EGFP-fusion plasmid 





2.10 RNA extractions 
2.10.1 Extraction and purification of small RNAs for Northern 
blotting 
Adherent cells were seeded in 25cm
2
 tissue culture flask (Corning) at a density of 5 x 
10
6
 cells and grown at 37°C with 5% (v/v) CO2 for 24 hours. Cells were then 
transfected as in Section 2.8.1 and grown for a further 48 to 72 hours at 37°C with 
5% (v/v) CO2. RNA was extracted using the mirVana miRNA isolation system 
(Ambion, USA) following the manufacturer‟s protocol. Briefly, a cell scraper was 
used to collect cells into 1 mL PBSA, and cells were pelleted by centrifugation for 5 
minutes at 10,000 g in a benchtop microcentrifuge (Sorvall), PBSA was removed and 
the pellet was resuspended in 600 µL of miRNA lysis/binding buffer. A 1/10
th
 
volume of miRNA homogenate additive was added to the lysate (60 µL), vortexed 
and incubated for 10 minutes on ice. Acid-Phenol:Chloroform extraction was 
performed using a volume of  Acid-Phenol:Chloroform (125:24:1, Ambion) equal to 
the original lysate volume (600 µL). Samples were then vortexed for 60 seconds and 
centrifuged at room temperature for 5 minutes at 10,000 g in a benchtop 
microcentrifuge (Sorvall). Upper aqueous phases were removed into fresh RNase-
free 1.5 mL tubes and the volumes recorded.  
 
The aqueous phase was mixed with 1/3 volume of 100% (v/v) ethanol by vortexing 
(200 µL) and passed through filter cartridges mounted in fresh 1.8 mL RNase-free 
collecting tubes by centrifugation at 10,000 g for 20 seconds. Volumes of filtrates 
(containing the small RNA fraction) were measured and a 2/3 volume of 100% (v/v) 
ethanol was added to precipitate the small RNAs. Samples were mixed by vortexing 
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and applied to a second filter cartridge in a fresh collecting tube, to bind the small 
RNAs. Samples were then centrifuged for 20 seconds at 10,000 g and filtrates were 
discarded. 
 
The filter cartridge was then washed with 700 µL miRNA wash solution 1 by 
centrifugation at 10,000 g for 10 seconds, then washed twice with 500 µL miRNA 
wash solution 2/3 by centrifugation at 10,000 g for 10 seconds, with the filtrate 
discarded after each step. Filter cartridges were then subjected to an additional 1 
minute centrifugation at 10,000 g to remove residual wash solution. Elution solution 
(Ambion) pre-heated to 95°C was used to elute bound RNAs off the filter cartridges. 
RNA was eluted into fresh RNase-free 1.8 mL collecting tubes by centrifugation at 
10,000 g for 60 seconds. 
 
2.10.2 TRIzol RNA extractions of total RNA 
Adherent cells were seeded in six well plates (Nunc, Denmark) at a density of 5 x 10
5
 
cells and grown at 37°C with 5% (v/v) CO2 for 24 hours. Cells were then transfected 
as in Section 2.8.1 and grown for a further 48 to 72 hours at 37°C with 5% (v/v) 
CO2. RNA was extracted using TRIzol Reagent (Invitrogen). Confluent cell 
monolayers were washed twice in PBSA, followed by addition of 1 mL of TRIzol 
Reagent (Invitrogen). Chloroform (200 µL) was added to each sample, and mixed by 
shaking for 15 seconds, samples were then incubated at room temperature for 3 
minutes followed by centrifugation at 12,000 g at 4°C for 15 minutes in order to 
separate the protein, DNA, and RNA phases. The aqueous phase, containing the 
RNA, was transferred to a clean RNAse free tube and 10 µg UltraPure Glycogen 
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(Invitrogen) and 500 µL Isopropanol was added. Samples were incubated for 10 
minutes at room temperature, followed by centrifugation at 12,000 g at 4°C for 10 
minutes. Supernatant was removed, and the pellet containing the RNA was washed 
with 1 mL 80% (v/v) ethanol with vortexing, followed by centrifugation at 7,500 g at 
4°C for 5 minutes. Ethanol was removed and the pellet was partially air-dryed before 
resuspension in 30 µL nfH2O preheated to ~55°C. Samples were incubated at 55°C 
for 5 minutes before being placed on ice. RNA was quantified and purity analysed 
using a spectrophotometer (NanoDrop ND-1000 3.3 Spectrophotometer, NanoDrop 
Technologies, USA), coupled to a computer (Optiplex GX280, Dell, USA). 
 
Sub-optimal purified RNA samples were further purified by addition of 90 µL 100% 
ethanol, 3 µL sodium acetate, and 10 µg UltraPure™ Glycogen (Invitrogen), mixed 
by pipetting and incubated for 24 hours at -20°C. RNA was pelleted by 
centrifugation at 12,000 g at 4°C for 10 minutes, supernatant was discarded and the 
pellet was washed in 80% ethanol. RNA was then re-pelleted by centrifugation at 
12,000 g at 4°C for 5 minutes. Ethanol was discarded and pellet was partially air-
dried before being resuspended in 30 µL nfH2O preheated to ~55°C. Samples were 
incubated at 55°C for 5 minutes. RNA was stored at -80°C. 
 
2.11 Northern blot analysis of shRNA processing 
2.11.1 Detection of siRNAs using radioactivity labelled LNA 
probes 
For Northern blots LNA probes were used to detect mature siRNA expression. LNA 
probes are short oligonucleotides comprised of deoxyribonucleic acid (DNA) 
 49 
  
nucleotides, interspersed with LNA monomers (Petersen et al. 2003). LNA 
monomers are modified ribonucleotides (2‟-O,4‟-C-methylene- -D-ribofuranosyl 
nucleotide), which feature a „locked‟ ribose sugar ring (2‟ and 4‟ hydroxyl groups are 
joined by a methylene (C2) bridge) (Petersen et al. 2000, Petersen et al. 2003). LNAs 
base-pair with high affinity to complementary RNA (Vester and Wengel 2004) and 
designed against mature miRNA sequences, have been used to detect miRNA 
expression in Northern blot analyses (Valoczi et al. 2004). LNA probes used are 
listed in Appendix A.   
 
2.11.2 Radioactive labelling of LNA probes and marker RNA 
LNA probes were custom designed and obtained un-labelled from Sigma-Proligo and 
labelled with radioactive gamma Phosphorous-32 deoxy-adenosinetriphosphate 
( -
32
P-dATP, Perkin Elmer), using polynucleotide kinase (Optikinase, USB 
Corporation). Labelling reactions contained: 1 µL of probe (10 pmol/µl), 2 µL 
-
32
P-dATP, 2.5 µL Optikinase 10X reaction buffer, 1 µL Optikinase enzyme and 
18.5 µL nfH2O (Promega), incubated at 37°C for 30 minutes then denatured at 100°C 
for 2 minutes. Probes were freshly labelled for each hybridisation and used 
immediately. For an indication of the size of separated RNA fragments by 
electrophoresis, the Decade Marker (mirVana Probe & Marker Kit, Ambion) was 
also end-labelled with -
32
P-dATP according to the manufacturer‟s instructions. 
 
2.11.3 Northern blotting 
DF1 cells were seeded at a density of 5 x 10
6
 cells/well in a 6 well plate (Nunc, 
Denmark) and incubated 24 hours at 37°C 5% (v/v) CO2 to obtain a confluency of 
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80%. Cells were transfected with plasmid DNA using Lipofectamine 2000. Briefly, a 
solution containing 5 µg of shRNA plasmid and 5µg of the relevant EGFP-fusion 
plasmid was mixed with 5 µL of Lipofectamine 2000 and transfected as outlined 
previously. RNA (<200 nt) was extracted from transfected cell cultures using 
miRvana miRNA isolation kits (Ambion). RNA samples were concentrated using 
Millipore microcon centrifugal filters (YM-30; Millipore, USA). Northern blots were 
performed as follows. Approximately 1 µg of low molecular weight RNA in a 
sample volume ≤25 µL was resolved on a 7M Urea-15% (w/v) polyacrylamide gel 
and transferred to a positively charged membrane (Hybond plus, Amersham 
Biosciences, USA) using a Trans-blot semi-dry transfer cell (BioRad, USA). The 
expression strength and processing efficiency of each hairpin was determined using 
the NP-LNA, or PB-LNA probe (Sigma- Proligo, USA) end-labeled with -
32
P-dATP 
using 10 U of OptiKinase (USB, USA). The U6 small nuclear LNA (U6 LNA) was 
used as a control to compare the amount of RNA loaded per well. Hybridisation was 
performed overnight at 42°C in 50% (v/v) formamide, 0.5% (w/v) sodium dodecyl 
sulfate (SDS), 5x saline sodium phosphate EDTA (SSPE), 5x Denhardts solution and 
100 µg/ml denatured herring sperm DNA (Roche, USA). Washing of the membrane 
was done three times in 2x SSC, 0.1% (w/v) SDS at 42°C.  
 
Autoradiographic exposure of PB or NP LNA probed membranes was carried out at 
-80°C for a period of 5 days for the standard loop shRNA northern blots, and 7 days 
for the miRloop shRNA northern blots, exposure of U6 LNA probed membranes was 
carried out at -80°C for a period of 2 hours. Stripping of probe off the membrane was 
done by placing the membrane in a solution containing 10 mM Tris pH 7.4 and 0.2% 
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(w/v) SDS and gradually heating the solution to 100°C over a 10 minute period, 
before re-probing of the membrane with a different LNA. Band sizes of resolved 
RNA were determined by comparison with Decade marker (mirVana Probe & 
Marker Kit, Ambion). 
 
2.11.4 Band intensity expression analysis 
Relative immature shRNA and mature siRNA expression levels were calculated from 
comparison of Northern blot band intensities using the ImageJ (v1.36b, 2006, Wayne 
Rasband, NIH, USA) „Analyze gels‟ function. The intensities of bands produced by 
sequence specific probes (E.g. PB1-2257) were divided by U6 band intensities for 
each sample to give normalised band intensities (Appendix B). The resulting 
intensity value for the immature shRNA and mature siRNA bands were then 
combined to produce a total band intensity value per sample. In order to obtain the 
processing efficiency (%) presented in the graphs the intensity value for the mature 
siRNA band was divided by the total band intensity and multiplied by 100. 
Calculations were carried out using Microsoft Excel (Microsoft Corporation) and 
graphs generated using Prism5 software (v5.03, GraphPad Software Inc, 2009).  
 
2.12 Detection of expressed shRNAs by RPA 
2.12.1 Radioactive labelling of probe RNA and marker RNA 
RNA oligonucleotides complimentary to the sense strands of PB, NP, and PA (Ge et 
al., 2003) were synthesised (TD287, TD203, and TD204 respectively), and diluted to 





(Amersham Biosciences) using the mirVana Probe & Marker Kit (Ambion) 
following the manufacturers instruction. Briefly, 1 μL of the diluted probe (1 pmol) 
was end labelled with 3.34 pmol of -
32
P-dATP (10 mCi/ml), 10 Units of T4 PNK, 1 
x kinase buffer, and water up to 10 µL. In addition to the PB, NP, and PA shRNA 
probes, the mouse miRNA miR-16 RNA probe provided as a positive control with 
the mirVana Probe & Marker Kit (Ambion) was also end-labelled with -
32
P-dATP 
using a similar reaction. For an indication of the size of separated RNA fragments by 
electrophoresis, the Decade Marker (mirVana Probe & Marker Kit, Ambion) was 
also end-labelled with -
32
P-dATP according to the manufacturer‟s instructions. 
 
2.12.2 TRIzol isolation and hybridization of small RNAs  
The isolation of RNA from transfected cells (see Section 2.8.1) enriched for small 
RNA was achieved using the TRIzol Reagent (Invitrogen) following a slightly 
modified version of the manufacturers protocol (see Section 2.10.2). In order to 
enrich for small RNA species 10 µg of UltraPure™ Glycogen (Invitrogen) was used 
as a carrier of RNA to the aqueous phase. Eluted RNA was quantified and stored at -
80°C until required. To hybridise the enriched RNAs to the labelled RNA probe (see 
Section 2.12.1), the mirVana miRNA Detection Kit (Ambion) was used according to 
the manufacturer‟s instructions. For each RNA sample, 1.5 μg of RNA was mixed 
with 1 μL of either the PB, NP, PA shRNA probe or the miR-16 control probe and 1 




2.12.3 Separation of RNA on denaturing agarose gels and 
autoradiography 
Electrophoretic separation of RNAs prepared in Section 2.12.2 was performed on 
denaturing 7 M Urea, 15% (w/v) acrylamide gels that were prepared as follows: 12.6 
g of Urea was mixed with 3 mL 10 x TBE buffer (0.9 M Tris base, 0.9 M Boric acid, 
20 mM EDTA pH 8.0) and 11.25 mL of 40% (w/v) acrylamide/bis (19:1), and made 
up to 30 mL with nuclease-free water. After thorough stirring to dissolve all Urea, 
150 μL 10% (w/v) ammonium persulphate (APS) and 20 μL of N, N, N‟, 
N‟-tetramethylethylene diamine (TEMED) were added and the solution was poured 
between glass plates using 1 mm spacers. Gels were left at room temperature for 
approximately 1 hour and then run in a Vertical Gel Electrophoresis System 
(Bethesda Research Laboratories) at 40 mA for 1 hour in 1 x TBE prior to loading of 
the RNA samples. All RNA samples were mixed with Gel Loading Buffer II 
(mirVana Probe & Marker Kit, Ambion) and heated at 95°C prior to loading. 
 
Separation was achieved by running gels at 40 mA for approximately 2 hours. Gels 
were then removed and enclosed with one sheet of Hyperfilm™ ECL (Amersham 
Biosciences) in an EC-AWU Cassette (Fuji) and stored at -80°C for the required 
exposure time. The exposed film was then removed and developed using an X-ray 




2.13 Complementary DNA Synthesis 
2.13.1 DNAse treatment of RNA samples for cDNA synthesis 
Complementary DNA (cDNA) was prepared from RNA for use in qRT-PCR (see 
Section 2.14) to compare expression of shRNAs within the coRNAi expression 
constructs. Reactions were prepared in 200 µL PCR tubes (Astral Scientific, 
Australia) and incubations were carried out using a thermal cycler (MasterCyclerS, 
Eppendorf). 
 
Total RNA enriched for small RNAs prepared using the TRIzol method (see Section 
2.10.2) was used for cDNA synthesis for qRT-PCR. Prior to cDNA synthesis, all 
RNA samples were DNaseI (RQ1, Promega) treated to remove potential genomic 
DNA contamination. Reactions were performed using 8 µL RNA, 1 µL 10x RQ1 
Reaction Buffer (Promega), 1 µL RQ1 DNaseI (Promega), incubated at 37°C for 30 
minutes, then 1 µL of RQ1 STOP solution (Promega) was added followed by further 
10 minute incubation at 65°C. DNaseI treated samples were used immediately for 
cDNA synthesis, or stored at -20°C. 
 
2.13.2 First strand cDNA synthesis 
DNAse treated RNA samples were poly-adenylated according to the approach 
described previously by Shi and Chiang (Shi and Chiang 2005). Poly-adenylated 
reactions contained 8 µL (1 µg) of DNAseI treated total RNA, 0.25 µL (150 U) of 
Yeast Poly(A) Polymerase (PAP) (USB, Cat #74225), 4 µL 5X PAP Reaction Buffer 
and 1 µL of 10nM rATP (Ambion) and nfH2O (Promega) in a final volume of 20 µL. 
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Reactions were incubated at 37°C for 30 minutes then at 95°C for 5 minutes and 
used immediately for first-strand cDNA synthesis. 
 
First strand cDNA synthesis was performed using Superscript® III (Superscript® III 
First Strand Synthesis Supermix (Invitrogen) according to manufacturer‟s 
instructions for oligo-dT primed RNA. For qRT-PCR, cDNA synthesis was primed 
using the modified oligo-dT primer miR-PTA (see Appendix A). The annealing 
reaction contained 4 µL of poly-adenylated RNA, 3 µL of 25 µM miR-PTA and 1 µL 
of Annealing Buffer and was incubated at 65°C for 5 minutes. First-strand cDNA 
synthesis reactions primed with miR-PTA were incubated at 50°C for 50 minutes, 
and inactivated by incubation at 85°C for 5 minutes. Samples were stored at -20°C. 
 
2.14 Quantitative reverse transcriptase PCR 
2.14.1 Analysis of expression 
The method of qRT-PCR used in this study for analysis of shRNA expression is 
based on the protocol devised by Shi and Chiang (Shi and Chiang 2005). This 
method uses cDNA reverse-transcribed from poly-adenylated total RNA using the 
miR-PTA primer (see Section 2.13.2). A specific forward primer designed to detect 
total expression or immature shRNA expression and a universal reverse primer 
(PAM-URP) that recognises the 3‟ adapter sequence present in the miR-PTA primer, 
detect expression of the target sequence. All primers used for qRT-PCR are listed in 




The total expression specific forward primers for the MWH constructs were designed 
using the mature siRNA strand sequence, with the addition of 2-4 “G” or “C” 
nucleotides at the 5‟ end in order to obtain melting temperatures close to that of the 
PAM-URP. The specific immature shRNA forward primers were designed using the 
loop sequence of the shRNA with bases added to the 5‟ from the 5‟ strand of the 
shRNA until a melting temperature equivalent to that of the mature forward primer 
was reached. 
 
All qRT-PCR was performed using SYBR Green detection reagents and 
StepOnePlus real-time PCR system (reagents, machine and software, Applied 
Biosystems). SYBR Green dye binds to double-stranded DNA (dsDNA) and 
produces a fluorescent signal. By measuring SYBR Green fluorescence intensity 
following each cycle, an amplification profile for a specific target sequence can be 
generated.  
 
Reactions were analysed in triplicate in 96-well format (MicroAmp PCR plates, 
Applied Biosystems). According to optimised parameters, cDNA was used at 1:50 
dilution and all primers were used at a final concentration of 200 nM. Each well 
contained 2 µL cDNA, 10 µL SYBR Green PCR Master Mix (Applied Biosystems), 
0.8 µL of forward target sequence specific primer, 0.8 µL of PAM-URP and nfH2O 
to a final volume of 20 µL. Cycle settings for all reactions were: 95°C 10 minutes, 
95°C 15 seconds, 60°C 1 minute (40 cycles). Melt curve analysis: 95°C 15 seconds, 
60°C 1 minute, ramp +0.3°C/s, 95°C 15 seconds (1 cycle). Chicken 5S RNA (5S) 
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was used as the reference control for normalising expression levels and data analysis 
was carried out using the comparative Ct method (see Section 2.14.2) 
 
2.14.2 Data analysis for qRT-PCR 
All qRT-PCR analysis was performed using the comparative Ct method, also known 
as the 2-delta-ΔCt (2-ΔΔCt) method (Livak and Schmittgen 2001; Schmittgen and 
Livak 2008). This generates an expression profile for the target that is normalised 
against a reference gene. For all qRT-PCR results in this thesis, expression levels are 
shown as a fold difference relative to the level of a selected reference sample, where 
the fold difference of the reference sample has a value of 1. 
 
For the purpose of explaining the qRT-PCR data analysis methods the following 
definitions apply: “target” refers to the sequence being detected (E.g. PB1-2257); 
“sample” refers to the treatment (I.e. shRNA transfected); “reference gene” (ref. 
gene) refers to the gene used to normalise expression of the target (I.e. 5S); 
“reference sample” refers to the sample (untransfected) against which expression 
levels are calculated as relative fold differences; “Ct value” is the cycle threshold 
value used to calculate the expression level; “delta-Ct” (ΔCt) is the difference 
between the Ct of the target and the Ct of the reference gene; “delta-delta-Ct” (ΔΔCt) 
is the difference between the ΔCt of the sample and the ΔCt of the reference sample; 






For data analysis Ct values for qRT-PCR were calculated by the StepOnePlus 
software based on a set Ct threshold of 0.1. For 2- ΔΔCt calculations, amplification 
data were then downloaded in tab delimited format from StepOnePlus software and 
imported into Microsoft Excel (Microsoft Corporation). Calculations were then 
performed for each target per sample as follows [Excel formulas indicated in square 
brackets]: 
1 – Mean Ct target/ref. gene: [=AVERAGE (cell range for triplicate Ct 
values)] 
2 – ΔCt sample/ref. sample: [=(mean Ct target)-(mean Ct ref. gene)] 
3 – ΔΔCt sample: [=(ΔCt sample)-( ΔCt ref. sample)] (NB: ref. sample = 0) 
4 – FD value: [=POWER(2,-(ΔΔCt sample)] (NB: ref. sample = 1) 
Average fold differences (± standard error of the mean, SEM) were calculated for 
each siRNA/shRNA from 3 biological replicates per sample, each replicate obtained 
from an independent experiment. Within each experiment three technical replicates 
were performed per sample. Statistical comparisons between samples (I.e. control 
versus treatment) were performed using an un-paired student t test (GraphPad Prism 
5 software) or a one-way ANOVA, where the threshold for statistical significance 
was set at 0.05. Graphs were generated using Prism 5 software (GraphPad) depicting 
sample/treatment on the x axis and relative expression (fold) on the y axis. Asterisks 
indicate the level of statistical significance (* p<0.05).   
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CHAPTER 3. Optimisation of shRNAs 
3.1 Introduction 
Expressing shRNA molecules from a plasmid is one method of inducing a long 
lasting RNAi response (Brummelkamp et al., 2002). Short hairpin RNA molecules, 
such as those targeting a virus, will continue to be expressed from the plasmid for as 
long as it remains in the cell, resulting in a strong antiviral strategy. 
 
However, expression of a shRNA does not guarantee efficient production of the 
actual downstream targeting unit, the siRNA duplex. Processing of the shRNA into 
the siRNA depends on the transport of the shRNA from the cell nucleus into the 
cytoplasm via Exportin-5, and removal of the shRNA loop nucleotides by Dicer. 
Therefore the amount of siRNA produced relies on the processing efficiency, rather 
than depending solely on the initial amount of shRNA expressed. 
 
Along with the benefits of using shRNAs comes an important point of consideration. 
Expressing large amounts of any RNA not native to an organism can be detrimental 
to its health and survival, and overloading of the cellular RNAi pathway by flooding 
it with non-endogenously expressed shRNA molecules has been shown to cause 
cellular toxicity (Grimm et al., 2006). It is suggested that increasing the processing 
efficiency of a molecule could reduce the requirement in the amount of shRNA 
expressed while still obtaining production of enough mature siRNA to obtain the 




As shRNAs are the artificial counterpart of endogenous pre-miRNAs and pre-
miRNAs are likely to have undergone evolutionary selection, it has been surmised 
that exploiting structural or sequence based aspects of pre-miRNAs may improve the 
effectiveness of shRNAs (Boden et al., 2004; Cullen, 2006; Zeng et al., 2002). 
 
Previous work has shown that the cleavage of the shRNA loop sequence plays a 
major part in the processing of the molecule (Hinton et al., 2008; McManus et al., 
2002b), and therefore this step will be the focus of this study. In order to increase the 
processing efficiency of the selected antiviral shRNAs, loop sequences were selected 
from native chicken pre-miRNAs that were determined to exhibit high amounts of 
mature miRNA via work done with microarray and deep sequencing technology by 
colleagues (Glazov et al., 2008). The effect of using a pre-miRNA derived loop 
sequence on the processing efficiency was determined by Northern blot, and the 
effect on suppressive activity of these molecules was determined against EGFP-
fusion plasmids and H1N1 virus. 
 
3.2 Results 
3.2.1 Standard loop shRNAs 
The standard loop shRNAs shPB1-2257, shNP-1498, and shNP-1496 contain a 9 nt 
loop sequence (Brummelkamp et al., 2002) and a siRNA duplex which targets 
influenza A (see Section 2.5.2). Analysis of the processing and suppressive activity 
of the three shRNAs was performed. The molecules were first investigated by 
Northern blot analysis in order to obtain insight into any differences in processing 




3.2.1.1 Processing efficiency of the standard loop shRNAs 
DF1 cells were transfected with the shRNA expression plasmids and after 72 hours 
were examined for shRNA expression by Northern blot (Figure 3.1a). Transfected 
DF1 cell extracts were enriched for small RNAs and separated on a 7M Urea-15% 
(w/v) polyacrylamide gel before transfer to a positively charged membrane, the 
membrane was then hybridised with a radiolabelled probe specific to a target 
sequence. PB and NP radio-labelled LNA probes complimentary to the guide 
sequences within the shRNAs were used to detect both immature shRNA (~60 nt) 
and mature siRNA (~20 nt) bands. The target sequences of shNP-1496 and shNP-
1498 differ in position by only 2 nt so the same LNA probe could be used for 
detection. A LNA probe for U6 small nuclear RNA was used as a loading control. 
 
The intensity of each detected band was measured using ImageJ. The processing 
efficiency (%) of each shRNA was then calculated as described in Section 2.11.4. 
The processing efficiencies detected for shNP-1498 and shNP-1496 were 37% and 
35%, whereas shPB1-2257 obtained a much lower value of 13% (Figure 3.1b). 
Therefore the NP standard loop shRNAs appear to be more efficiently processed than 
shPB1-2257. The Northern blot indicated that although shPB1-2257 is strongly 
expressed with a total band intensity of 2.24 (Appendix B (a)) from the chU6-4 
promoter there is very little detectable processing of the molecule through the RNAi 
pathway into its mature siRNA form. The U6 loading control LNA showed equal 






Figure 3.1 Processing efficiency of the standard loop shRNAs 
(a) Processing efficiencies of the three standard loop shRNAs shPB1-2257, shNP-1498, and 
shNP-1496, were determined by Northern blot. Low molecular weight RNA extracted from DF1 cells 
transfected with shRNAs was resolved 1 µg per lane on a 7M Urea-15% (w/v) polyacrylamide gel and 
transferred to a positively charged membrane. The membrane was separately probed with PB and NP 
LNAs and exposed to film for 5 days each time. The membrane was also probed with the U6 LNA 
and exposed to film for 2 hours. These blots verify expression of the shRNAs and show that the 
shRNAs exhibit differential processing efficiency, although all expressed from the chU6-4 promoter. 
(b) Band intensity relative to U6 was calculated, and the processing efficiency was calculated by 
























































































































































Once the processing efficiency of the standard loop shRNAs had been analysed the 
next step was to investigate the ability of these molecules to suppress a target. This 
was done by testing their effectiveness against EGFP-fusion plasmids. 
 
3.2.1.2 EGFP-fusion plasmid suppressive activity of the standard 
loop shRNAs 
Analysis of the suppressive activity of the standard loop shRNAs was assayed using 
EGFP-fusion plasmids (see Section 2.5.1). Successful targeting of the influenza gene 
segment of the EGFP-fusion transcript was measured as a decrease in EGFP 
fluorescence compared to control cells. This provides a readily measurable way of 
determining the ability of a shRNA to suppress the translation of the target gene. 
 
DF1 cells were co-transfected with a standard loop shRNA and a relevant 
EGFP-fusion construct and the average level of EGFP expression for three replicates 
each was measured by flow cytometry 72 hours post transfection. The MFI for each 
transfection condition was then calculated (Section 2.9). 
 
Results showed each of the three standard loop shRNAs are able to produce 
suppression of the relevant EGFP-fusion construct, pEGFP-NP or pEGFP-PB 
(Figure 3.2). There was no significant difference between the ~60% decrease in 
fluorescence of pEGFP-NP produced by shNP-1498 and the ~40% decrease 
produced by shNP-1496. The shPB1-2257 molecule resulted in a ~30% reduction in 













Figure 3.2 EGFP-fusion suppressive activity of the standard loop shRNAs 
The suppressive efficiencies of the three standard loop shRNAs (shPB1-2257, shNP-1498 and 
shNP-1496) were tested against pEGFP-PB and pEGFP-NP. 500 ng of the relevant fusion was tested 
against 500 ng of a standard loop shRNA. Flow cytometry was used to determine the mean 
fluorescence intensity (MFI) for each condition 72 hours post-transfection. The fluorescence produced 
by the EGFP-fusion plasmids alone was set at 100% and all other samples compared to that. Error 
bars represent the SEM calculated from duplicate samples in three individual experiments. Columns 




























































This research indicated that different molecules expressed from identical promoters 
can have different processing and suppressive efficiencies. The next step was to 
investigate optimisation of these molecules by focusing on the loop sequence. The 
shNP-1496 and shPB1-2257 molecules were chosen for optimisation due to the 
differences in processing observed. 
 
3.2.2 Antiviral shRNAs with miRNA derived loops 
Antiviral shRNAs were designed with loop sequences derived from chicken 
pre-miRNAs. These molecules were called miRloop shRNAs. Selection of the 
pre-miRNAs was based on the structures of the pre-miRNAs, expression levels of the 
mature miRNAs produced, and also knowledge of the processing efficiency of some 
pre-miRNAs. For convenience purposes within this thesis the terminology of 5‟ 
strand and 3‟ strand is used to refer to the sequence within the pre-miRNA that is 5‟ 
of the loop and the sequence that is 3‟ of the loop respectively. 
 
The structures of a number of highly expressed pre-miRNAs were screened, and the 
pre-miRNAs selected were among those with the least number of unpaired regions or 
„bulges‟ in their secondary structures residing outside of the terminal loop area. This 
was done so that the closest imitation of the natural pre-miRNA structures could be 
obtained without the insertion of mismatches in the siRNA duplex. Structures were 
produced for the chicken pre-miRNAs and the miRloop shRNAs using m-fold 




































































































































































































































Figure 3.3 Structures of miRNAs and miRloop shRNAs 
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Figure 3.3 Structures of miRNAs and miRloop shRNAs 
(a) Structures of standard loop molecules containing the 9 nt Brummelkamp loop (Brummelkamp et 
al., 2002) (b) RNA folded structures (mfold (Zuker, 2003)) of the three selected chicken miRNA 
(gga-miR-122-1, gga-miR-107, gga-miR-19b) with the blue outline showing the sequence defined by 
this study as the loop, and the red showing the sequence of the mature guide strand. All pre-miRNA 
structures have been cropped to show only the area containing the loop and predicted mature strand. 
(c) RNA folded structures of the miRloop shRNAs produced (NPmiR122, NPmiR107, NPmiR19b, 
PBmiR122, PBmiR107, and PBmiR19b). The structure with the highest ΔG was selected when more 
than one predicted structure was provided by mfold. The blue outline shows the loop sequences and 




Chicken pre-miRNAs miR-122 and miR-107 were selected due to results obtained by 
this laboratory showing high expression of the mature miRNA in a number of 
chicken tissues across a range of time points. Pre-miRNA-19b was selected due to 
previous work by this laboratory having found that it has a high processing efficiency 
(Cottee et al., unpublished).  
 
Although miR-122 is predicted to express from the 5‟ strand, all miRloop shRNA 
molecules were designed with the desired mature sequence on the 3‟ strand. This was 
based on strong evidence in the literature showing that the characteristics that 
contribute to one strand of an shRNA being incorporated into RISC more often than 
the other are likely to reside in the duplex (Gu et al., 2011; Hutvagner, 2005; 
Khvorova et al., 2003; Schwarz et al., 2003) rather than within the loop. 
 
The shRNA loop structures were compared to the structure of the pre-miRNA loops 
in order to ensure that any structural characteristics required for processing would be 
present in the miRloop shRNAs designed. The loop region defined in miR-122 is 
composed of 12 unpaired nucleotides, and this unpaired region is maintained in all 
the miR-122 loop shRNA m-folds. The miR-107 loop region contains two unpaired 
areas separated by a paired area (3 nt), and contains another paired area (2 nt) at the 
base, and this native secondary structure is maintained in the miR-107 loop shRNA 
m-fold predicted structures. The miR-19b m-fold structure contains a large unpaired 
region (13 nt) with a small paired area at the base (2 nt) and this is again maintained 




Once the miRloop shRNAs were produced the first question we wished to investigate 
was whether the use of a miRNA derived loop would affect the processing efficiency 
of the shRNAs. 
 
3.2.2.1 Processing efficiency of miRloop shRNAs  
Before testing the ability of the miRloop shRNAs to induce suppression the 
processing of these molecules was analysed. DF1 cells were transfected with 
shRNAs (Section 2.8.1) and analysed for shRNA expression by Northern blot 
(Section 2.11) after 72 hours (Figure 3.4a and Figure 3.5a). PB and NP radio-labelled 
LNA probes complimentary to the guide sequences within the shRNAs were used to 
detect both immature shRNA (~60 nt) and mature siRNA (~20 nt) bands. The U6 
loading control LNA for both blots showed that some samples contained less RNA 
than others. This was adjusted for in calculating the band intensities by normalising 
the original measured intensity for each band to the relevant U6 band. 
 
Results clearly indicated that PBmiR107 is more efficiently processed (28%) than the 
other PB miRloop shRNAs (Figure 3.4b). Processing efficiencies obtained were 7% 
for PBmiR19b and 0% for PBmiR122. The standard loop molecule shPB1-2257 also 
obtained a low processing efficiency of 7%. 
 
The processing efficiency of the miRloop shRNAs containing the NP-1496 siRNA 
duplex was also determined by Northern blot (Figure 3.5b). NPmiR19b and 




Figure 3.4 Processing efficiency of the PB miRloop shRNAs 
(a) Processing efficiencies of the miRloop shRNAs containing the PB1-2257 siRNA sequence 
(PBmiR122, PBmiR107, and PBmiR19b) were determined by Northern blot. Low molecular weight 
RNA extracted from DF1 cells transfected with shRNAs was resolved 1 µg per lane on a 7M Urea-
15% (w/v) polyacrylamide gel and transferred to a positively charged membrane. The membrane was 
probed with the PB LNA and exposed to film for 7 days each time. The membrane was also probed 
with the U6 LNA and exposed to film for 2 hours. (b) Band intensity relative to U6 was calculated, 
and the processing efficiency was calculated by dividing the mature band intensity by the total band 



































































































Figure 3.5 Processing efficiency of the NP miRloop shRNAs 
(a) Processing efficiencies of the miRloop shRNAs containing the NP-1496 siRNA sequence 
(NPmiR122, NPmiR107, NPmiR19b) were determined by Northern blot. Low molecular weight RNA 
extracted from DF1 cells transfected with shRNAs was resolved 1 µg per lane on a 7M Urea-15% 
(w/v) polyacrylamide gel and transferred to a positively charged membrane. The membrane was 
probed with the NP LNA and exposed to film for 7 days each time. The membrane was also probed 
with the U6 LNA and exposed to film for 2 hours. (b) Band intensity relative to U6 was calculated, 
and the processing efficiency was calculated by dividing the mature band intensity by the total band 



































































































respectively. NPmiR122 obtained a processing efficiency of 11%, compared to the 
48% of the standard loop shNP-1496. Both the PB and NP miR-122 loop molecules 
obtained a processing efficiency less than the standard loop molecules containing the 
same siRNA duplexes. 
 
The Northern blot of the NP miRloop molecules does not exhibit a concise processed 
siRNA band for NPmiR107 and NPmiR19b. Human Dicer cleavage prediction 
software PHDcleav predicted only siRNA sized products of 18-21 nt for these 
molecules suggesting that the somewhat spread out appearance of the NPmiR107 and 
NPmiR19b siRNA bands may be due to an experimental factor such as DNA 
contamination of the RNA samples. For the purposes of estimating the processing 
efficiency of the molecules the whole band area was included in the band intensity. 
Repeats of this experiment obtained similar relative band intensities for these 
molecules. 
 
Another potential explanation for the appearance of the NPmiR107 and NPmiR19b 
siRNA bands is that the shRNA molecules were incompletely processed. This could 
happen as a result of using the sequence of a loop from a native miRNA and 
incorporating it into a synthetic siRNA cassette. This possibility is supported by the 
observation that the smears within these lanes appear to contain bands that are 
smaller than the unprocessed shRNA but larger than a siRNA molecule. Further 
work would need to be done in order to determine whether the detected species of 
RNA are products of incomplete processing. One potential approach to this would be 




Human Dicer prediction software was also used to gather further information about 
the miR-122 loop molecules. The cleavage sites predicted result in 17 nt and 16 nt as 
the guide strand lengths most likely to be produced for PBmiR122 and NPmiR122 
respectively, with no full length guide strand products likely to be produced by either 
miR-122 loop hairpin. 
 
Now that the processing of the miRloop shRNAs had been investigated the next step 
was to determine the ability of these molecules to suppress a target. This was initially 
done against individual targets in the form of EGFP-fusion plasmids. 
 
3.2.2.2 EGFP-fusion plasmid suppressive activity of miRloop shRNAs 
Analysis of suppressive activity of the miRloop shRNA molecules was assayed using 
EGFP-fusion plasmids. Successful targeting of the influenza gene sequence segment 
of the EGFP-fusion plasmids results in a decrease in EGFP fluorescence due to the 
influenza gene segment and the EGFP gene being processed as a single transcript. 
This gives an indication of the ability of a shRNA to suppress a gene. DF1 cells were 
co-transfected with a shRNA and a relevant EGFP-fusion construct and the average 
level of EGFP expression for three replicates each was determined 72 hours post 
transfection. Flow cytometry was used to determine the MFI for each transfection 
condition. 
 
PB miRloop shRNAs were tested against pEGFP-PB and results showed that all 
molecules were able to significantly decrease fluorescence. No significant difference 
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was found between the suppression produced by any of these molecules (Figure 
3.6a). NP miRloop molecules were tested against pEGFP-NP (Figure 3.6b), and all 
NP molecules except NPmiR122 produced a significant decrease in fluorescence. 
There was no significant difference in the decrease produced by shNP-1496, 
NPmiR107 or NPmiR19b. 
 
Once the EGFP-fusion assay had been used to determine the ability of the molecules 
to target a sequence and decrease transcription, it was important to test the ability of 
the molecules to target the sequence within an actual viral gene. The influenza A 
H1N1 PR8 strain was used in this study. 
 
3.2.2.3 H1N1 virus suppressive activity of miRloop shRNAs 
The H1N1 influenza A virus suppressive activity of the miRloop shRNAs was 
initially measured by HA assay, and then confirmed by performing virus titrations. 
The live virus titres were determined as the TCID50/mL of the virus supernatants 
taken from cells treated with the shRNAs, obtained using the Reed and Muench 
method (Reed and Muench, 1938). Observation of CPE in the form of distinct 
plaques was performed at day five and day seven post infection (PI). HA assays give 
a positive result if any virus is detected, even if it is no longer able to replicate. Using 
CPE as a measure to determine live virus titre is a much more reliable method of 
determining the virus suppressive activity of a molecule. In this study both methods 






















Figure 3.6 EGFP-fusion suppressive activity of the miRloop shRNAs 
(a) mirloop shRNAs containing the PB1-2257 siRNA sequence (PBmiR122, PBmiR107, and 
PBmiR19b) were tested against pEGFP-PB. (b) mirloop shRNAs containing NP-1496 siRNA 
sequence (NPmiR122, NPmiR107, NPmiR19b) was tested against pEGFP-NP. 500 ng of the relevant 
fusion was tested against 500 ng of a standard loop shRNA. Flow cytometry was used to determine 
the mean fluorescence intensity (MFI) for each condition 72 hours post-transfection. The fluorescence 
produced by the EGFP-fusion plasmids alone was set at 100% and all other samples compared to that. 
Error bars represent the SEM calculated from duplicate samples from four individual experiments. An 
asterisk on the negative control means all other samples are significantly different (p≤0.05) to that 
control. Otherwise, an asterisk (*) on a column indicates that sample is significantly different to the 











































































































HA titres indicated that shPB1-2257 was the most efficient at suppressing viral 
growth out of those targeted to the PB gene (Figure 3.7a), and NPmiR107 was the 
most efficient out of those targeted to the NP gene (Figure 3.8a). Results also showed 
that PBmiR122 and NPmiR122 are ineffective at suppressing the virus. The 
supernatants taken from cells which had been transfected with PBmiR122 or 
NPmiR122 and infected with virus had higher titres then all other transfection 
conditions, including the irrelevant hairpin control shEGFP. 
 
Live virus titres of the PB miRloop shRNA supernatants (Figure 3.7b) calculated 
from CPE analysis at day five showed that there was no significant difference 
between the infectious virus present in the irrelevant hairpin control shEGFP and 
PBmiR122 samples. A significant decrease (p≤0.05, unpaired two-tailed t-test) in 
virus was observed in the shPB1-2257 and PBmiR19b samples, compared to the 
shEGFP sample. By day seven no significant difference was observed in virus titres 
between the different conditions. Live virus titre of the NP miRloop shRNA 
supernatants (Figure 3.8b) calculated from CPE analysis at day five showed no 
difference between the infectious virus present in the shEGFP and NPmiR122 
samples. The shNP-1496, NPmiR107 and NPmiR19b hairpins significantly reduced 
viral titres (p≤0.05, unpaired two-tailed t-test). At day seven the titre of infectious 







Figure 3.7 H1N1 suppressive activity of PB miRloop shRNAs 
MDCK cells were transfected with shEGFP, shPB1-2257, PBmiR122, PBmiR107, or PBmiR19b 
before being infected with H1N1 in duplicate at three MOIs: 0. 1, 0.01, and 0.001. (a) HA assays were 
performed on supernatants taken from infected cells, the HA titre was determined as the highest 
dilution of virus where haemagglutination occurred. (b) TCID50/mL assays were performed on 
supernatants taken from cells infected with virus at an MOI of 0.1. The TCID50/mL of each molecule 
was calculated based on the dilution of virus supernatant which resulted in CPE in 50% of the infected 
wells in a virus titration experiment. Error bars are SEM calculated from duplicate samples in two 
individual experiments. An asterisk (*) on a column indicates that sample is significantly different 



























































































































Figure 3.8 H1N1 suppressive activity of NP miRloop shRNAs 
MDCK cells were transfected with shEGFP, shNP-1496, NPmiR122, NPmiR107, or NPmiR19b 
before being infected with H1N1 in duplicate at three MOIs: 0. 1, 0.01, and 0.001. (a) HA assays were 
performed on supernatants taken from infected cells, the HA titre was determined as the highest 
dilution of virus where haemagglutination occurred. (b) TCID50/mL assays were performed on 
supernatants taken from cells infected with virus at an MOI of 0.1. The TCID50/mL of each molecule 
was calculated based on the dilution of virus supernatant which resulted in CPE in 50% of the infected 
wells in a virus titration experiment. Error bars are standard deviation calculated from duplicate 
samples in a single experiment. Where no error bars are seen the standard deviation was not great 
enough to generate error bars. An asterisk (*) on a column indicates that sample is significantly 
different (p≤0.05, unpaired two-tailed t-test) to the irrelevant hairpin (shEGFP control). A plus sign 

































































































































3.3.1 Processing and suppressive activity of standard loop 
shRNAs 
In a study performed by McIntyre et al. (McIntyre et al., 2011b) it was found that 
approximately 60% of the 101 studies surveyed on the expression of shRNAs used 
the same 9 nt loop sequence UUCAAGAGA (Brummelkamp et al., 2002). In the 
years since the original publication of this loop sequence there has been great interest 
in the possibility of improving the effectiveness of a shRNA by optimising the loop 
sequence selected for incorporation into the molecule. 
 
This study aimed to investigate the effect of incorporating three different native 
chicken miRNA derived loop sequences into selected shRNAs targeted to H5N1 AI, 
in place of the ubiquitously used loop published in 2002 (Brummelkamp et al., 
2002). Prior to investigating this we analysed the effectiveness of three shRNAs 
previously used to suppress H5N1 by this laboratory, in order to enable a comparison 
with the newly created miRloop shRNAs. 
 
Analysis of the processing of the standard loop molecules was performed by 
Northern blot (Figure 3.1). This study found that the shPB1-2257 shRNA, previously 
observed by this laboratory to be the most potent at decreasing H5N1 virus 
production, was the least efficiently processed to the mature siRNA. This was 
unexpected given that the high suppressive effectiveness suggested high production 
of mature siRNA. Similar processing efficiencies were observed for the two NP 
targeting shRNAs, with slightly more processing observed from the shNP-1498 
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molecule. H5N1 viral suppression experiments showed shNP-1498 to be a far more 
effective molecule than shNP-1496, with the level of suppression produced close to 
that of shPB1-2257. 
 
Analysis of the suppressive activity of the standard loop molecules was performed 
using an EGFP-fusion assay (Figure 3.2). No significant difference was found in the 
suppressive activity of the two NP molecules against pEGFP-NP, however 
shNP-1498 produced a slightly greater reduction of EGFP fluorescence. This agrees 
with the processing result obtained for these two molecules. The PB targeting hairpin 
shPB1-2257 was found to produce weak suppression of pEGFP-PB. 
 
There are a few possible explanations for the inconsistencies in processing efficiency 
and the ability to reduce viral titre. The first of these which is put forward is that it is 
possible that some processed mature siRNA escapes detection using the Northern 
blot method as it moves so efficiently through the RNAi pathway and is degraded 
prior to detection. The Northern blot provides the equivalent of a snapshot of the 
RNA species present in the cell at the time of lysis, and therefore may not be the 
most accurate measure of processing when it comes to potentially extremely efficient 
shRNAs. 
 
The second explanation to be explored is that the differences observed between 
processing efficiency and viral titre reduction ability could suggest a deviation in the 
way in which cells derived from avian and mammalian species treat hairpin RNAi. 
The EGFP-fusion suppression and processing analysis assays were performed in the 
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DF1 cell line, a continuous cell line of chicken embryo fibroblasts, whereas the 
H1N1 virus suppression experiments were performed in the MDCK cell line, a 
continuous cell line of canine kidney fibroblasts. 
 
A third explanation could be that although the shPB1-2257 molecule appears to be 
less efficiently processed than the NP targeting molecules, it is possible that PB plays 
such an important role as a polymerase subunit that it is a much more effective target 
for RNAi, resulting in the virus being highly susceptible to any decrease in PB. 
 
3.3.2 miRNA derived loops affect processing and suppressive 
activity 
Many factors contribute to the ability of an RNAi inducing molecule to produce 
effective suppression. Boden et al. (Boden et al., 2004) composed a list of these 
factors, which we reiterate here with minor modification:  
 the structural stability of the RNAi inducing molecule 
 export of the RNAi inducing molecule from the nucleus 
 the ability of the RNAi inducing molecule to be processed by Dicer 
 the incorporation of the produced siRNA into RISC 
 the nucleotide homology of the siRNA to the target sequence 
 the accessibility of the target RNA  
 
This study focused mainly on the ability of the RNAi inducing molecule to be 
processed by Dicer, and specifically on the effect that use of a miRNA derived loop 




The pre-miRNA loop sequences selected for incorporation into the antiviral shRNAs 
were taken from the chicken genome due to a potential downstream application of 
this work being the production of transgenic chickens. The miR-107 and miR-19b 
pre-miRNAs express the mature miRNA from the 3‟ strand, whereas miR-122 
contains the mature sequence on its 5‟ strand. 
 
The structure of miR-122 was analysed in order to determine if it contained 
characteristics within the duplex which were likely to result in the 5‟ strand being 
primarily incorporated into RISC (Gu et al., 2011; Hutvagner, 2005; Khvorova et al., 
2003; Schwarz et al., 2003). The pre-miRNA contains mismatches at the 5‟ end of 
the mature sequence on the 5‟ strand which generate a lower thermodynamic stability 
at that end, which is likely to result in the 5‟ strand being preferentially incorporated 
into RISC. Based on this information the antiviral shRNA containing the loop taken 
from the miR-122 was produced with the desired mature sequence on the 3‟ strand as 
were all the other miRloop shRNAs produced. It is worth noting that if the entire 
pre-miRNA structure was being mimicked and bulges introduced into the duplex, 
then placing the desired mature sequence on the same strand as in the pre-miRNA 
would be necessary as the thermodynamic characteristics in the miRNA would be 
carried over into the siRNA duplex. 
 
It was found that incorporation of the miR-122 derived loop produced very 
inefficient processing (Figure 3.4 and 3.5) and suppression of EGFP-fusion plasmids 
(Figure 3.6). The processing efficiency of the miR-122 loop molecules was lower 
 83 
  
than the processing of the standard loop hairpins for both siRNA sequences. This 
indicates that there is a characteristic within the loop or the hairpin produced by 
incorporation of the loop that negatively affects either export of the hairpin from the 
nucleus by Exportin-5, cleavage of the loop by Dicer, or incorporation of the siRNA 
guide strand into RISC. 
 
Firstly the possibility of the problem pertaining to export of the hairpin or the 
incorporation of the siRNA into RISC will be discussed. At the time that this study 
was being performed there had been little research done into the effect of the loop 
sequence on the export of an shRNA from the nucleus by Exportin-5, other than that 
greatly decreasing the size of the miR-30 loop can impair its export (Zeng and 
Cullen, 2004), and that some artificially designed loops result in nuclear retention of 
shRNAs (Kawasaki and Taira, 2003). Given that these studies also found that the 
miRNA derived loops tested were observed to increase Exportin-5 binding rather 
than impair it, it seems unlikely that nuclear retention of the miR-122 loop shRNAs 
is the cause of the effects observed. Furthermore, the miR-122 pre-miRNA is known 
to produce high amounts of miRNA, suggesting that this loop sequence would enable 
efficient Exportin-5 binding of an miRNA or shRNA which contained it. As for the 
possibility of there being a problem with incorporation into RISC; the sequences of 
the two siRNA duplexes are identical between the different miRNA derived loops 





Looking back at the m-fold predicted secondary structures of the miRloop shRNAs, 
and specifically at the ΔG calculated for each predicted structure, we see that the two 
miR-122 loop shRNAs have much lower local folding potentials (higher ΔGs) and 
therefore have lower structural stability. The structural stability of an shRNA has 
previously been correlated with the ability of an shRNA to be processed to siRNA 
(Boden et al., 2004). Boden et al. (2004) deduced that a high structural stability 
could allow rapid folding back of the shRNA into the hairpin secondary structure, 
making the hairpin available for Dicer binding and cleavage and therefore increasing 
the rate of processing. For that reason it is suggested that the cause of the low 
processing and suppressive activity of the miR-122 loop shRNAs is their 
comparatively low structural stability. 
 
Analysis of the processing of the miR-107 and miR-19b loop containing shRNAs 
showed that PBmiR107, NPmiR107, and NPmiR19b exhibit increased processing 
when compared to the relevant standard loop shRNA (Figure 3.4 and Figure 3.5). 
The m-fold predicted structures of these miRloop shRNAs have greatly increased 
structural stability (lower ΔGs), which is likely to be the reason for their increased 
processing (Boden et al., 2004). PBmiR19b also has a high structural stability but no 
increase in processing efficiency was observed compared to the standard loop 
shPB1-2257. As this result was specific to PBmiR19b we suggest it was caused by 
an interaction of the sequence of nucleotides at the base of the loop with the miR-19b 




Although no significant difference in the EGFP-fusion suppressive activity was 
observed for any of the PB miRloop molecules or the standard loop shPB1-2257, we 
wish to point out that previous experiments performed by colleagues that have used 
the EGFP-PB fusion construct have found that its susceptibility to suppression is 
quite poor. This is potentially due to the mRNA secondary structure produced by the 
addition of the PB gene segment sequence to the EGFP sequence within the 
EGFP-fusion construct, which may be very different to the structure of the native 
RNA targeted by the shRNAs. The trend of the graph in Figure 3.6a appears to be 
that the standard loop molecule and the PBmiR122 molecule produce similar levels 
of suppression, and that a slightly stronger suppression may be produced by 
PBmiR107 and PBmiR19b. 
 
Interestingly, no increased suppression of the NP gene EGFP-fusion construct was 
observed with NPmiR107 or NPmiR19b. This indicates that an increase in 
processing efficiency does not always correlate with an increase in the ability of a 
shRNA to suppress a target gene. This result is in agreement with other work 
published by colleagues at AAHL (Hinton et al., 2008). 
 
3.3.2 miRNA derived loops affect virus suppressive activity 
After ascertaining that usage of miRNA derived loops does affect processing 
efficiency, and that suppressive activity can be affected as a result of this; we wished 
to determine the effect of miRNA derived loops on suppression of genes within a 
viral model. Influenza A H1N1 PR8 was selected as the viral target due to the 
following reasons. The target sequences of the shRNAs being tested are 100% 
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conserved between both H5N1 and H1N1; and initial siRNA sequence investigation 
work was done with H1N1 PR8 (Ge et al., 2003). 
 
Analysis of the virus suppressive activity of the miRloop molecules by HA assay and 
determination of the live virus titre as TCID50/mL found that the miR-122 loop 
molecules were unable to produce any decrease in virus titre (Figure 3.7 and 3.8). It 
is likely that this is a result of the inefficient processing of the hairpins to siRNAs, 
which has been postulated to have been caused by the low structural stability of the 
miR-122 molecules resulting in a decreased rate of Dicer cleavage (Boden et al., 
2004) as discussed previously. Analysing the shRNA sequences using Human Dicer 
cleavage site prediction software PHDcleav suggested that no full length guide strand 
products are likely to be produced by either miR-122 loop hairpin, and that the 
lengths most likely to be produced are 2-3 nt shorter than the full length siRNA stem. 
It is thought that this shortening in the siRNA guide strand could result in an increase 
in nonspecific targeting and therefore decrease the amount of siRNAs that guide 
RISC to cleave the correct mRNA. 
 
The miR-19b loop shRNAs were observed to be the most effective at targeting the 
different viral genes. Although the processing efficiency of PBmiR19b was not 
improved from the standard loop shPB1-2257 (Figure 3.4), the shPB1-2257 molecule 
itself was observed to be highly effective at producing suppression (Figure 3.7). The 
similar levels of processing measured for these two molecules appeared to agree with 
their equivalent suppressive abilities. NPmiR19b and NPmiR107 were both observed 
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to have increased processing efficiency compared to shNP-1496 (Figure 3.5), but 
were observed to produce an equivalent level of virus suppression (Figure 3.8). 
 
The processing efficiency of PBmiR107 was shown to be higher than that of 
shPB1-2257 (Figure 3.4), but no decrease in viral titre was found (Figure 3.7). It has 
previously been observed that processing efficiency is not always directly indicative 
of suppressive activity (Hinton et al., 2008). It is worth noting that there is 
potentially a large amount of variability between targeting a partial gene sequence in 
an EGFP-fusion construct and targeting a gene sequence within a virus, one 
important difference being the change in target availability due to differing 
secondary structures. Another method that can be used to rapidly determine whether 
an RNAi molecule is likely to suppress the targeted viral gene is the dual-luciferase 
reporter system which involves both firefly luciferase and Renilla luciferase, 
however this and any reporter system used is likely to face the challenge previously 
mentioned therefore it is important to test molecules against the virus itself to get an 
accurate measurement of their effectiveness. 
 
As discussed in Section 3.3.1 there is also an alternative explanation for the 
inconsistencies found between the processing efficiency and viral suppressive 
activity observed. These differences could suggest a deviation in the way in which 
cells derived from avian and mammalian species process hairpin RNA, as the 
EGFP-fusion suppression and processing analysis assays were performed in a 
chicken cell line, whereas the H1N1 virus suppression experiments were performed 
in a canine cell line following the guidelines set out by the WHO Manual on Animal 
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Influenza Diagnosis and Surveillance (WHO, 2002) and best practice as regarded by 
the OIE. Future work will examine our constructs in chicken cells using low and high 
pathogenic AI virus strains, allowing processing and viral suppression data to be 




This work was carried out in order to determine if the incorporation of miRNA 
derived loops into influenza A targeting shRNA molecules could affect the activity 
of these molecules. It was found that incorporation of miRNA loops can affect both 
the processing efficiency and the viral suppressive activity of a shRNA. The impacts 
of using a miRNA derived loop varied depending on the loop selected, with one of 
the  loops tested resulting in a decrease in processing efficiency and viral suppressive 
activity while others were found to increase processing efficiency. These differing 
effects could largely be attributed to the stability of the hairpin structures produced 
by incorporation of the different loop sequences. It is therefore important to analyse 
the predicted structures prior to producing the shRNAs. 
 
It was also found that changes in activity produced by incorporation of miRNA 
derived loops can vary depending on the siRNA sequence within the molecule. 
Identical loop sequences were observed to cause an increase in the processing of one 
shRNA while having no effect on another. We propose that further research needs to 
be done into this in order to establish what structural or sequence based characteristic 




Once we had investigated the optimisation of individual RNAi inducing molecules 
we wished to move on to an investigation of coRNAi. Highly mutating viruses are 
able to escape RNAi strategies where a single sequence is targeted, therefore 
coRNAi is necessary. In order to effectively use coRNAi to prevent viral escape it is 
important to further our understanding of the factors which affect multiple expression 





CHAPTER 4. Investigating coRNAi against influenza 
4.1 Introduction 
RNAi has been used successfully to suppress many viruses in vitro including AI (Li 
et al., 2005), and HIV-1 (Lee et al., 2002a), however the high mutation rate of RNA 
viruses means that ultimately these viruses escape RNAi strategies which target a 
single sequence within the virus. This results in monotherapeutic antiviral strategies 
rapidly becoming ineffective, leading to the need to continually develop new 
vaccines which are effective against the new strains of virus. Issues with viral escape 
from single target RNAi treatments have been reported in a number of viruses 
including poliovirus (Gitlin et al., 2002; Gitlin et al., 2005), HCV (Randall et al., 
2003; Wilson and Richardson, 2005), and HIV (Boden et al., 2003; Das et al., 2004; 
Lee et al., 2005; Westerhout et al., 2005). 
 
A study performed by Leonard and Schaffer (2005) looked at viral escape using a 
computational model of HIV replication which took into account details of HIV 
reproduction and vulnerability to RNAi. They found that viral escape could be 
prevented in 100% of trials using an RNAi strategy involving three molecules of 
75% efficiency or four molecules of 70% efficiency. Their results also showed that a 
strategy which involved five molecules of 60% efficiency was unable to prevent viral 
escape. Therefore prevention of viral escape requires the targeting of multiple gene 
sequences with molecules of high suppressive activity. 
 
Reducing the risk of viral escape can be achieved by developing strategies involving 
coRNAi, which involves combining multiple RNAi inducing molecules in a single 
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construct. This allows the targeting of multiple conserved sequences within a gene, 
or targeting conserved sequences within a number of genes, and in doing so greatly 
increases the likeliness of avoiding escape mutants. Many different methods of 
coRNAi have been investigated and comparisons of these have found the MTU 
strategy, or MWH, to produce the most reliable suppression of multiple gene targets 
(Lambeth et al., 2010; McIntyre et al., 2011a). 
 
Transcription of MTUs such as MWHs produces multiple individual shRNAs which 
can each contain different target sequences. This method also enables the use of 
promoters of different strengths for different shRNAs. Previous work by this 
laboratory has found differences in the effectiveness of the shRNAs within a MWH, 
thought to be related to their position within the MWH. The MWH constructs in this 
study were designed to test this. 
 
Previous research using the chU6-4, chU6-3, and chU6-1 chicken promoters selected 
for use in this study has shown that they exhibit different levels of expression in Vero 
cells compared to chicken cells (DF1 cell line) (Bannister et al., 2007; Wise et al., 
2007). In chicken cells the promoters produce a similar degree of suppression, 
whereas in Vero cells the chU6-3 and chU6-4 promoters are much stronger than 
chU6-1. In order to further investigate these differences we decided to analyse the 
expression and EGFP-fusion suppressive activity of the MWH constructs in both 





4.2.1 The MWH constructs 
In this study four MWH constructs were produced, two with three promoter-shRNA 
cassettes and two with two promoter-shRNA cassettes (Figure 4.1). The siRNA 
sequences selected for incorporation were PB1-2257, NP-1496 and PA-2087 (Ge et 
al., 2003). Optimisation of single antiviral shRNAs was investigated previously 
(Chapter 3), and from this work the miR-107 derived loop sequence was selected for 
incorporation into the shRNAs contained within the MWHs. The resulting 
PBmiR107, NPmiR107, and PAmiR107 were transcribed by chU6-4, chU6-3, and 
chU6-1 promoters respectively. The cassettes within the MWH constructs were 
arranged based on promoter strengths deduced from previously published research in 
monkey cells (Vero) (Wise et al., 2007). The expression strengths of the promoters 
were found to be less diverse in chicken cells (DF1 and COV-1 cells) (Bannister et 
al., 2007; Kudo and Sutou, 2005; Wise et al., 2007). In the strong-to-weak (stw) 
constructs the chU6-4 cassette was placed first, followed by the chU6-3 in the two 
cassette construct, and with the chU6-1 following the chU6-3 in the three cassette 
construct. In the weak-to-strong (wts) constructs the chU6-1 cassette was placed first, 
followed by the chU6-3 in the two cassette construct, and with the chU6-4 following 















Figure 4.1 Producing the MWH constructs 
(a) One step PCR was used to produce three individual transcription units containing a SalI 
recognition site, chicken pol. III promoter (chU6-4, chU6-3, or chU6-1) and the shRNA (sense strand, 
loop, antisense strand, terminator sequence, and XhoI recognition sequence). (b) By ligating the three 
transcription units together in different orders and combinations (using the compatible SalI and XhoI 
sites on the 5‟ and 3‟ ends of the PCR products) four MWH constructs were produced- wts2, wts3, 
stw2, and stw3 (wts: weak-to-strong, stw: strong-to-weak). The wts2 and wts3 constructs contain the 
weakest U6 promoter, chU6-1, first. The stw2 and stw3 MWH constructs contain the strongest chU6 
promoter, chU6-4, first. U63-NPmiR107 resides in the second position in all constructs. 
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4.2.2 Confirmation of hairpin expression from MWH constructs 
Confirmation of expression of shRNAs from the MWH constructs was performed in 
chicken cells. DF1 cells were co-transfected with one of the MWH expression 
vectors and pEGFP-NP, or an individual hairpin and the relevant EGFP-fusion 
plasmid (Section 2.8.1). Total RNA was extracted 72 hours after transfection and 
enriched for small RNA (Section 2.10.2) before being analysed by RPA (Section 
2.12). 
 
Presence of bands of approximately 20 nt in size verified MWH expression of small 
RNAs complimentary in sequence to the probes (Figure 4.2). RNA samples extracted 
from cells transfected with wts2 showed no detectable band when hybridised to the 
PB probe, as was expected due to this MWH construct not containing a PB targeting 
hairpin. There was also no band detected in the cell sample transfected with stw2 
when probed for the PA sequence, as expected as this MWH construct does not 
contain a PA targeting hairpin. All MWH constructs contained a NP targeting 
hairpin, as was shown by the hybridisation products present in all samples analysed. 
Analysis showed that hairpins were expressed from all three promoters in all of the 
different positions tested. 
 
In addition to the probes used to detect the shRNAs, a radio-labelled miRNA probe 
with homology to murine miR-16 was used to confirm the presence of RNA in each 
sample analysed. All samples are hybridised and loaded separately therefore this 
probe cannot be used as a true loading control in terms of the quantity of RNA 




















Figure 4.2 Confirmation of expression from MWH constructs 
DF1 cells were co-transfected with a MWH expression vector and pEGFP-NP, or an individual 
hairpin and the relevant EGFP-fusion plasmid (E.g. PBmiR107 and pEGFP-PB). Total RNA enriched 
for small RNA was isolated 72 hours post-transfection. Radiolabelled probes PB (a), NP (b) and PA 
(c) were used to detect expression of the shRNA molecules. Radiolabelled miR16 (d) was used to 








































































































hybridisation with the specific probes did indeed contain RNA. The miR-16 probe 
detected a homologous miRNA in all samples tested, confirming integrity of RNA in 
all samples. 
 
Confirmation of hairpin expression in DF1 cells from each of the different chU6 
promoters within the MWH constructs suggested that each of these hairpins could be 
used to induce suppression of a target. Next qRT-PCR was performed to enable 
comparison of expression of the shRNAs in the different MWHs. 
 
4.2.3 Quantitative analysis of expression from MWH constructs 
in chicken cells 
Quantitative analysis of the expression of shRNAs from the MWH constructs was 
performed by qRT-PCR. To measure the expression of the shRNAs, DF1 cells were 
co-transfected with a plasmid expressing a MWH construct and pEGFP-NP, as all 
MWHs contain a molecule targeting the NP sequence. 
 
Analysis of the expression of shRNAs from the MWH constructs in DF1 cells used 
primers which contained the loop sequence (Figure 4.3a). Expression of PBmiR107 
was consistent in all MWHs. Expression of NPmiR107 was found to be significantly 
higher in stw2 and stw3 than in wts2, and expression from stw3 was significantly 
higher than from wts3. PAmiR107 was found to be most highly expressed in stw3 







Figure 4.3 Quantitative analysis of expression from MWH constructs in chicken 
cells 
Expression from the MWH constructs was analysed by qRT-PCR using specific forward primers to 
detect (a) shRNA expression and (b) total expression including shRNA and siRNA. Error bars 
represent the SEM calculated from duplicate samples in three individual experiments. Where no error 
bars are seen the SEM was not sufficient to generate them. An asterisk (*) on the untransfected (un) 
means all other columns in that group are significantly different (p≤0.05) to the untransfected. 
Otherwise, an asterisk (*) on a column indicates that sample is significantly different to the relevant 
untransfected. (a) Columns marked with a plus (+) are significantly different to the wts2 in that group, 
columns marked with an arrowhead (^) are significantly different to stw3 within that group. (b) 
Columns marked with a plus (+) are significantly different to the wts2 in that group, columns marked 
with an arrowhead (^) are significantly different to wts3 within that group. Expression was normalised 




































































































































A total measure of expression of both shRNA and siRNA was obtained using primers 
made up of sequence taken from the predicted mature strand, these primers do not 
contain any loop sequence and therefore are able to detect both immature shRNA and 
mature siRNA (Figure 4.3b). Significantly more expression of PBmiR107 was 
detected from stw2 and stw3 than the untransfected control. NPmiR107 was more 
highly expressed from stw2 and stw3 than from wts2 and wts3. 
 
Quantitative analysis of expression of shRNAs from the MWH constructs was also 
performed in Vero cells in order to allow comparison between avian and mammalian 
cells. 
 
4.2.4 Quantitative analysis of expression from MWH constructs 
in mammalian cells 
Analysis of the expression of shRNAs from the MWH constructs was also performed 
by qRT-PCR. To measure the expression of the shRNAs, Vero cells were 
co-transfected with a plasmid expressing a MWH construct and pEGFP-NP. No 
significant expression of the PBmiR107 shRNA was detected from any MWHs when 
compared to the untransfected control (Figure 4.4a). Significantly higher expression 
of NPmiR107 shRNA was found from wts3 than from wts2, and significantly higher 
expression of PAmiR107 shRNA was found from stw3 than from wts2. Significantly 
higher total expression of PBmiR107 was detected in stw2 than in the untransfected 
control (Figure 4.4b). Total expression of NPmiR107 and PAmiR107 was 
significantly higher in wts2 than in the untransfected control. Compared to the other 





Figure 4.4 Quantitative analysis of expression from MWH constructs in 
mammalian cells 
Expression from the MWH constructs was analysed by qRT-PCR using specific forward primers to 
detect (a) shRNA expression and (b) total expression including shRNA and siRNA. Error bars 
represent the SEM calculated from duplicate samples in three individual experiments. Where no error 
bars are seen the SEM was not sufficient to generate them. An asterisk (*) on the untransfected means 
all other columns in that group are significantly different (p≤0.05) to the untransfected. Otherwise, an 
asterisk (*) on a column indicates that sample is significantly different to the relevant untransfected. 
Significance symbols: (a) Columns marked with a plus (+) are significantly different to any other 
column in that group marked with a plus (+). (b) Columns marked with a plus sign (+) are 






































































































































expression detected. This suggests a decrease in the amount of shRNA detected, and 
an increase in the amount of siRNA detected. 
 
Analysis of hairpin expression in Vero cells from the MWH constructs suggested 
that each of these hairpins could be used to induce suppression of their target genes. 
The next step was to assay the suppressive activity of the molecules, firstly against 
individual targets in the form of EGFP-fusion plasmids. This was done in DF1 and 
Vero cells. 
 
4.2.5 Individual suppressive activity of the MWH constructs in 
chicken cells 
Analysis of the individual suppressive activity of the cassettes within the MWH 
constructs was assayed using the pEGFP-PB, pEGFP-NP and pEGFP-PA 
EGFP-fusion plasmids (Section 2.5.1). DF1 cells were co-transfected with a miRloop 
shRNA and a relevant EGFP-fusion construct (Section 2.8.1) and the average level 
of EGFP expression was determined 72 hours post transfection by flow cytometry 
(Section 2.9). Relative MFI for each transfection condition was then determined as a 
percentage of the negative control (Figure 4.5). 
 
No significant difference was found in the ability of any of the MWHs or PBmiR107 
to suppress pEGFP-PB. When testing against pEGFP-NP results showed that all 
molecules significantly decrease fluorescence produced by pEGFP-NP, with wts3 
significantly less effective than the individual NPmiR107. Analysing the ability of 












Figure 4.5 Individual suppressive activity of MWH constructs in chicken cells 
The individual suppressive efficiencies of the cassettes within the four MWH constructs (stw2, stw3, 
wts2 and wts3) were tested against pEGFP-PB, pEGFP-NP and pEGFP-PA. The individual hairpin 
cassettes (PBmiR107, NPmiR107 and PAmiR107) which make up the MWH constructs were also 
included. 500 ng of the relevant fusion was tested against 500 ng of a MWH or individual hairpin by 
co-transfection into DF1 cells. Flow cytometry was used to determine the mean fluorescence intensity 
(MFI) for each condition 72 hours post-transfection. The fluorescence produced by the EGFP-fusion 
plasmids alone was set at 100% and all other samples compared to that. Error bars represent the SEM 
calculated from duplicate samples in three individual experiments. An asterisk on the negative control 
means all other columns in that group are significantly different (p≤0.05) to that control. Otherwise, 
an asterisk (*) on a column indicates that sample is significantly different to the relevant negative 
control. Columns with a plus (+) are significantly different to any other column within that group 




































































































significantly, with wts2 found to be a significantly better at suppressing pEGFP-PA 
than stw3. 
 
4.2.6 Individual suppressive activity of the MWH constructs in 
mammalian cells 
Analysis of the individual suppressive activity of the cassettes within the MWH 
constructs was assayed in Vero cells following the same protocol as in DF1 cells. 
Vero cells were co-transfected with a miRloop shRNA and a relevant EGFP-fusion 
construct (Section 2.8.1) and the average level of EGFP expression was determined 
72 hours post transfection. Relative MFI for each transfection condition was then 
determined as a percentage of the negative control (Figure 4.6). 
 
No significant difference was found in the ability of any of the MWHs or PBmiR107 
to suppress pEGFP-PB. Analysing the ability of molecules to suppress pEGFP-PA 
showed that only wts2 was effective at reducing fluorescence. Significant reduction 
of the fluorescence produced by pEGFP-NP was achieved only by wts2, and 
NPmiR107. It was observed that the pEGFP-NP suppressive activity of MWHs was 
reduced when the chU64-PBmiR107 cassette was co-expressed. 
 
Once the individual suppressive activity of the cassettes within the MWHs was 
determined, the net suppressive activity of each MWH construct was investigated 













Figure 4.6 Individual suppressive activity of MWH constructs in mammalian 
cells 
The individual suppressive efficiencies of the cassettes within the four MWH constructs (stw2, stw3, 
wts2 and wts3) were tested against pEGFP-PB, pEGFP-NP and pEGFP-PA. The individual hairpin 
cassettes (PBmiR107, NPmiR107 and PAmiR107) which make up the MWH constructs were also 
included. 500 ng of the relevant fusion was tested against 500 ng of a MWH or individual hairpin by 
co-transfection into Vero cells. Flow cytometry was used to determine the mean fluorescence intensity 
(MFI) for each condition 72 hours post-transfection. The fluorescence produced by the EGFP-fusion 
plasmids when not suppressed was set at 100% and all other samples compared to that. Error bars 
represent the SEM calculated from duplicate samples in three individual experiments. An asterisk on 
the negative control means all other columns in that group are significantly different (p≤0.05) to that 
control. Otherwise, an asterisk (*) on a column indicates that sample is significantly different to the 



































































































4.2.7 Net suppressive activity of MWH constructs against H1N1 
The net suppressive activity of the MWH constructs to inhibit H1N1 viral replication 
in MDCK cells was initially measured by HA assays, and then confirmed by 
performing virus titrations. The live virus titres were determined in the form of the 
TCID50/mL of the virus supernatants taken from cells which had been treated with 
the MWHs prior to infection with virus. Observation of CPE in the form of distinct 
plaques was performed at day five and day seven post infection (PI). HA titres 
(Figure 4.7a) indicated that shPB1-2257 was the most efficient at suppressing viral 
growth, followed by stw2. The wts2 sample contained a higher titre of virus at all 
MOIs tested than all other samples, including shEGFP. Live virus titres (Figure 4.7b) 
showed no significant difference between any samples at day five PI, but at day 
seven PI the shPB1-2257 and stw2 samples contained a significantly lower amount 
of virus than shEGFP. No significant difference was found between the virus 
suppression produced by stw2 and shPB1-2257. The stw3 construct was observed to 
be slightly less effective at suppressing virus compared to stw2, but this difference 
was not significant. 
 
It was observed that wts3 and stw2 produced significantly better suppression than 
wts2, with the wts2 construct observed to increase virus titre compared to shEGFP. 
No significant difference was found between the two constructs containing three 





Figure 4.7 Net suppressive activity of MWH constructs against H1N1 
The net suppressive efficiencies of each of the four MWH constructs were tested against H1N1. 
MDCK cells were transfected with MWH expression vectors before being infected H1N1 in duplicate 
at three MOIs: 1, 0.1, and 0.01. (a) HA assays were performed on supernatants taken from infected 
cells, the HA titre was determined as the highest dilution of virus where haemagglutination occurred. 
(b) TCID50/mL assays were performed on supernatants taken from cells infected with virus at an MOI 
of 0.1. TCID50/mLs were calculated based on the dilution of virus supernatants which resulted in CPE 
in 50% of the infected wells in a virus titration experiment. Error bars represent the standard deviation 
calculated from duplicate samples in a single experiment. Where no error bars are shown the standard 
deviation was not sufficient to generate them. An asterisk (*) on a column indicates that sample is 
significantly different (p≤0.05) to the irrelevant hairpin (shEGFP control). Any other type of symbol 







































































































4.3.1 Analysis of hairpin expression 
The MWH constructs were confirmed to express hairpins from all positions in DF1 
cells. Confirmation of shRNA expression from all promoters and positions within the 
MWH constructs allowed us to move onto the next step, using qRT-PCR to take a 
quantitative look at the expression of the shRNAs. 
 
The qRT-PCR analysis performed used two different forward primers. The shRNA 
primer was designed to be comprised mainly of the loop sequence contained within 
the targeted shRNA, along with the number of bases of the shRNA sense strand 
required in order to reach an annealing temperature similar to that of the other primer 
used, the total expression primer. The total expression primer contained only the 
siRNA antisense strand sequence and therefore was able to detect the presence of 
that sequence regardless of what form it was present in, shRNA or siRNA. The total 
expression detected by this primer is not able to be accurately separated into the 
different RNA species, therefore only comparisons of shRNA expression and total 
expression will be made. 
 
The primary interest was to determine whether or not the expression of shRNAs was 
altered by their positioning within a construct. Focusing on the shRNA expression 
(Figure 4.3a and Figure 4.4a) we observe that expression of the PBmiR107 hairpin 
from the chU6-4 promoter within the MWH constructs was consistent regardless of 
the cassettes position within the constructs, suggesting that position had no effect on 
expression in either cell type. Likewise, no difference was seen in the expression of 
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the PAmiR107 hairpin from chU6-1 when placed in the first or last position of a 
three hairpin construct. This suggests that the lack of positional effects on expression 
of PBmiR107 was not dependent on having a stronger promoter which may be able 
to negate potential issues with being at the end of a long construct. Therefore these 
results show no evidence of negative effects relating to positioning of a shRNA in 
the last position of a three promoter-shRNA cassette construct. 
 
This result supports previous research into MWHs and the possibility of positional 
effects (McIntyre et al., 2011a). McIntyre et al. (2011a) tested MWH constructs 
comprised of two, three, and four cassettes which contained a hairpin in one position 
and empty cassettes in all other positions. They tested the activity of the hairpin in all 
positions available within the MWH constructs, and were unable to detect any 
reduction in activity. It is proposed that previous losses in efficiency seen in MWH 
constructs which have been thought to be a result of positional effects may have been 
a result of competition of the shRNA molecules for access to components of the 
RNAi pathway such as Exportin-5 or Dicer. 
 
No evidence of hairpin competition was seen in analysis of DF1 cells; however 
results did show evidence of hairpin competition in Vero cells. Higher total 
expression, and lower unprocessed shRNA expression, was observed from chU6-3 
expressed NPmiR107 and chU6-1 expressed PAmiR107 from MWH constructs 
when there was no chU6-4 PBmiR107 co-expressed (Figure 4.4b). Previous research 
(Wise et al., 2007) has shown that there is a greater difference in expression 
strengths of the three promoters used when in Vero cells than in DF1 cells, with the 
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chU6-4 promoter observed to be much stronger than chU6-1. These results suggest 
that when the more highly expressed PBmiR107 hairpin is present it out competes 
the more weakly expressed hairpins for access to components of the RNAi pathway, 
and therefore decreases the amount of mature siRNA produced. 
 
Further research could be done to determine the levels of the different components of 
the RNAi pathway in Vero and DF1 cells, and would potentially provide insight into 
the observed differences in hairpin competition between the two cell lines. Western 
blotting has previously been used to do this in Hela, T47D and U87 cells with 
monoclonal antibodies specific to Dicer, Exportin-5, and other RNAi pathway 
components (Vickers et al., 2007) and this method could be employed here also.  
 
4.3.2 Suppressive activity of MWHs is independent of positional 
effects 
Comparison of expression from the different promoters in DF1 and Vero cells 
showed that the promoters have more varied effectiveness in the Vero cells than in 
the DF1 cells, as in agreement with previous findings (Wise et al., 2007). The 
strength of suppression produced from the three promoters in Vero cells showed 
chU6-1 to be the weakest, with similar suppression produced by chU6-3 and chU6-4 
(Figure 4.6). 
 
When looking at either cell line the suppressive activity of the PBmiR107 hairpin 
expressed from the chU6-4 promoter within the MWH constructs was observed to be 
consistent regardless of the cassettes position within the construct (Figure 4.5 and 
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Figure 4.6). There was also no difference in suppressive activity from PAmiR107 
expressed from the chU6-1 promoter when placed in the first or last position of a 
MWH construct (Figure 4.5 and Figure 4.6). This supports previous results from 
qRT-PCR analysis and also work done by McIntyre et al. (2011a) suggesting that 
there are no negative effects relating to positioning of a shRNA in the last position of 
a three cassette construct. 
 
Evidence of hairpin competition affecting the individual suppressive activity of the 
cassettes within the MWHs was seen in Vero cells but not DF1s. No decrease in the 
suppressive activity of the individual shRNAs within the MWHs against 
EGFP-fusion plasmids was observed in DF1 cells (Figure 4.5), however in Vero cells 
the suppressive activity of chU6-3 NPmiR107 was greatly reduced when chU6-4 
PBmiR107 was present (Figure 4.6). It is proposed that due to the greater differences 
in promoter expression strengths in Vero cells (Wise et al., 2007) it is more likely 
that weaker expressed hairpins would be out competed for access to RNAi pathway 
components by hairpins expressed at a higher level. Further investigation would need 
to be done to confirm this theory. 
 
4.3.3 Hairpin competition can reduce virus suppressive activity 
Influenza A H1N1 infection experiments showed differential virus suppressive 
abilities for the different MWH constructs. All molecules within the MWHs 
contained the miRloop sequence derived from miR-107; therefore differences in 
suppressive activity between the different MWHs were not produced as a result of 




Results obtained at Day 7 indicated that stw2 was the most effective of the MWHs, 
producing a level of suppression not significantly different to that of the individual 
standard loop shPB1-2257 (Figure 4.7b). The first position of the stw2 construct 
contains the PB1-2257 siRNA sequence which is known to be highly effective 
against influenza A H1N1 (Ge et al., 2003) expressed from the chU6-4 promoter 
known to produce strong expression (Bannister et al., 2007; Kudo and Sutou, 2005; 
Wise et al., 2007). This construct also contains only two cassettes, both of which 
contain effective siRNA sequences. It is likely that a combination of these positive 
attributes resulted in the high suppressive activity of this construct. 
 
Confining the construct to two strong cassettes avoids any decrease in effectiveness 
which might be caused by the inclusion of a third molecule which may only have 
weak antiviral activity. Whether the detrimental impact of incorporating a molecule 
with weak suppressive activity arises from competition for RNAi pathway 
components as thought (McIntyre et al., 2011a) or through another mechanism, is yet 
to be determined. 
 
The viral suppressive activity of the stw2 construct was not greater than the 
individual shRNA but due to the two target sequences contained in it would 
potentially provide better protection against viral escape. Further work would be 
needed to determine this and it is suggested that the methods used by von Eije et al. 
(2008) could be followed to do so, with a RNAi escape study performed to compare 
the protection provided by each MWH and the individual shRNA. Stably transfected 
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cell lines would be produced expressing each MWH and the individual shRNA and 
infected with virus at a low MOI. Serial passaging of the infected cells would then be 
used to select for replicating RNAi-resistant virus variants, and cell free virus 
collected.  The cell free virus would then be used to infect control cells lacking the 
shRNA as well as cells stably transfected with the shRNA in order to confirm that 
the virus variant was resistant. Virus would then be harvested and analysed using 
deep sequencing in order to identify the mutations present. 
 
It is noted that a decrease in suppressive activity was observed between stw2 and 
stw3, but this was not found to be significant (Figure 4.7b). Here it seems that the 
addition of a third cassette comprised of chU6-1 and a less effective siRNA sequence 
PA-2087 (Ge et al., 2003) has negatively affected the ability of the stw3 construct to 
inhibit viral growth. It is suggested that, as previously proposed, this occurs by the 
co-expression of the weaker molecule resulting in decreased availability of the RNAi 
pathway components to process the two stronger molecules (McIntyre et al., 2011a). 
Possibly the high anti-viral potency of the first cassette has reduced the measurable 
impact of this competition on the net suppressive activity of the construct (McIntyre 
et al., 2011a). 
 
The wts3 construct was found to be significantly more effective than wts2 (Figure 
4.7b). The wts2 construct contains only two cassettes, but is lacking the cassette 
made up of the stronger promoter and most potent siRNA sequence, and therefore it 
is not surprising that it has produced minimal suppression. The wts3 construct 
contains three cassettes, but in the last position is a highly efficient and strongly 
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expressed hairpin. In this MWH it appears that the effectiveness of the final cassette 
has increased the overall suppressive activity of the construct, therefore in this case 
inclusion of the third molecule was beneficial. 
 
No significant difference was found between wts3 and stw3 (Figure 4.7b). One 
possible explanation for this is that it the beneficial effect of including the third 
highly potent molecule in wts3 and the detrimental effect of including the third 
weaker molecule in the stw3 has resulted in an increase in overall suppressive 
activity of wts3 and a decrease in overall suppressive activity of stw3 that resulted in 
them producing a similar level of suppression. 
 
Other groups have also found evidence of competition between hairpins for access to 
important components of the RNAi pathway (Castanotto et al., 2007; Holen et al., 
2002; McIntyre et al., 2011a; McManus et al., 2002a); with co-expression of 
shRNAs resulting in the individual suppressive effectiveness of each hairpin being 
progressively reduced as increasing numbers of hairpins were co-expressed. 
Castanotto et al. (2007) observed competition between shRNAs, and between 
siRNAs and shRNAs, in human 293 cells and after thorough investigation concluded 
that this is likely due to competition at the level of incorporation into RISC rather 
than competition for Exportin-5. Based on research by other groups that 
over-expression of Exportin-5 can relieve saturation of nuclear to cytoplasmic 
transport of shRNAs in mice and men (Grimm et al., 2006; Yi et al., 2005), 
Castanotto et al. (2007) performed an experiment where they over-expressed 
Exportin-5 and co-transfected siRNAs along with a shRNA. They saw increased 
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overall activity of the shRNA, but found that competition between the different 
sequences persisted. Therefore they concluded that although siRNAs and shRNAs 
may compete for Exportin-5 the main competition observed is for incorporation into 
RISC. 
 
It is worth pointing out that although McIntyre et al. (2011a) observed hairpin 
competition when looking at the individual suppressive activity of hairpins within a 
MWH, they did not see a decrease in net suppressive activity when each hairpin 
co-expressed could contribute to the suppression of a single target. However, 
McIntyre et al. (2011a) stated that they only tested this using hairpins which were 
each highly active individually, not with one or more hairpins which were poor or 
completely inactive. PA-2087, one of the siRNA sequences included in the MWH 
constructs, has been found to produce weak suppressive activity as an siRNA tested 
against H1N1 (Ge et al., 2003), and as an shRNA tested against H5N1 and H1N1 by 
this laboratory. McIntyre et al. (2011a) speculated that if they had included a shRNA 
with poor suppressive activity they would have expected to see a reduction in the net 
suppressive activity produced, and the results found by this study support this theory. 
 
4.4 Conclusion 
Analysis of the activity of hairpins from within MWH constructs provided insight 
into the factors that affect the expression and suppressive activity of hairpins within 
this type of construct. In agreement with previously published research it was found 
that the positions chosen for placement of hairpins within these constructs have no 
impact on expression or suppressive activity. Furthermore, a reduction in net 
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suppressive activity of MWHs was found when a weak hairpin was included, 
indicating the presence of competition between hairpins for access to important 
components of the RNAi pathway. No evidence of hairpin competition was observed 
in DF1 cells when the individual suppressive ability of hairpins was investigated, 
however evidence of hairpin competition was found in Vero cells. This is potentially 
a result of the greater discrepancy in the expression strength of the different 
promoters in this cell type. 
 
Using the MWH strategy H1N1 viral suppression was produced at a level equal to 
that of the best individual anti-viral molecule identified so far by our laboratory. 
Although the suppression produced was not better than that produced by the 
individual shRNA, it would be expected to provide better protection against viral 
escape if used in therapeutic strategies due to the presence of targets in two different 
genes rather than just the single target. This could be confirmed by performing an 




CHAPTER 5. General Discussion 
 
RNAi has been successfully used to suppress many viruses both in vitro and in vivo. 
It can be applied to viruses and host cell receptors alike. Comparisons of available 
methods for inducing RNAi have found vector based expression of shRNAs to 
produce longer-lasting suppression than synthetically produced siRNAs, at a level 
sufficient to produce suppression of the target. Expression of shRNAs is commonly 
from RNA pol III promoters, with the U6 family of promoters providing a high level 
of expression and therefore being a favoured option. One drawback of the shRNA 
method is that expression of shRNAs has been found to present a risk of inhibiting 
endogenous miRNAs from traversing the RNAi pathway, leading to cellular toxicity 
(reviewed in Section 1.1.2.4).  
 
Optimisation of shRNA design has been investigated following the rationale that 
designing shRNAs which mimic pre-miRNAs will result in the shRNAs passing 
through the RNAi pathway more efficiently. Optimisation of shRNAs in this way 
should lead to an improvement in shRNA processing and therefore an increase in the 
mature siRNA which triggers degradation of the target. The increase in mature 
siRNA efficiently processed from the expressed shRNA will allow a reduction in the 
amount of shRNA initially expressed, while still producing a sufficient level of 
suppression. Once the processing efficiency has been increased the promoter in 





The design of shRNAs which more closely mimic pre-miRNAs has focused on the 
loop sequence, where the stem of the hairpin is left perfectly base-paired, and also on 
the overall structure of the shRNA. Research into altering loop sequences has found 
that results are dependent on the miRNA selected, with some loop sequences 
increasing processing efficiency and some decreasing it (reviewed in Section 
1.1.2.5). The design of shRNAs that mimic the overall structure of a selected pre-
miRNA, termed artificial pre-miRNAs, involves use of a pre-miRNA loop and 
incorporation of mismatches in the passenger strand in order to produce bulges 
similar to that present in the pre-miRNA . Artificial pre-miRNAs are generally 
expressed from a weaker RNA pol II promoter. These promoters allow inducible and 
tissue specific expression of RNAi, providing greater control over expression (Chung 
et al., 2006; Shin et al., 2006; Stegmeier et al., 2005). 
 
Given that shRNAs are a highly effective method of inducing RNAi but their use 
involves a risk of causing toxicity to the cell, the initial objective of this study was to 
improve the processing efficiency of shRNA molecules by testing different chicken 
pre-miRNA derived loop sequences. Chapter 3 described research into the 
optimisation of two antiviral shRNAs by the incorporation of loop sequences from 
pre-miRNAs selected using the following criteria: High expression of the mature 
miRNA and low number of structural bulges outside of the terminal loop area. This 
study found that while a loop sequence may result in an improvement in processing 
for one shRNA sequence it may not for a different shRNA. This was in agreement 
with work published by Schopman and colleagues while this study was being 
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performed, who stated that sequence and length of the shRNA stem can affect how a 
particular loop will work within a shRNA (Schopman et al., 2010).  
 
There was one loop which negated processing efficiency in both of the antiviral 
shRNAs. Analysis of the structures of shRNAs containing this loop, the miR-122 
loop, found that they exhibited low structural stability. Previous research (Boden et 
al., 2004) has indicated that a low structural stability can result in a decreased rate of 
processing of a shRNA to the mature siRNA. 
 
This study also looked into the relationship between processing efficiency of the 
shRNAs and their suppressive activity against H1N1 influenza A PR8. Results 
showed that an improvement in processing efficiency does not always result in an 
improvement in suppressive activity. Two possible reasons for this discrepancy are 
discussed in Section 3.3.1. Briefly, Northern blotting, the method used to determine 
the processing efficiency of the shRNAs, may not be able to accurately measure the 
processing of shRNAs which pass rapidly through the RNAi pathway and are 
potentially degraded prior to detection. Alternatively, this observation may be a 
result of a difference in how avian and mammalian cells treat hairpin RNAi, as the 
processing efficiencies were determined in chicken cells and the virus suppression 
experiments were conducted in canine cells.  
 
It is worth noting that the miRloop shRNAs containing the miR-122 loop were 
observed to exhibit both poor processing efficiency and weak suppressive activity. 
Dicer cleavage prediction software has suggested that it is likely that in addition to 
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their poor structural stabilities, these molecules produce siRNAs that are 2-3 nt 
shorter than the desired product. This increases the likeliness of the siRNAs 
producing nonspecific targeting rather than specific targeting of the viral gene. The 
miRloop shRNAs most effective at suppressing H1N1 influenza A PR8 were also 
those with the highest structural stability, the miR-19b loop shRNAs. The findings of 
this research suggest that the structural stability of a shRNA impacts on both the 
shRNAs processing efficiency and suppressive activity, despite the observation that 
detection of a poor processing efficiency does not always correlate with poor 
suppressive activity and vice versa. 
 
The sequence specificity of RNAi makes it ideal for degrading desired targets while 
leaving non-complementary sequences untouched, however the ability of viruses to 
alter their genomes by producing point mutations allows them to escape RNAi 
strategies which target a single sequence. A study performed using a computational 
model of HIV replication (Leonard and Schaffer, 2005) determined that viral escape 
could be prevented by targeting multiple gene sequences with high efficiency. They 
found that targeting a single sequence with a shRNA of average effectiveness, 70%, 
prevented viral escape in 0% of trials, while four shRNAs of this efficiency 
prevented viral escape in 100% of trials. The results also showed that RNAi inducing 
molecules of 60% were unable to prevent viral escape even when five different 
sequences were targeted. Therefore in order to prevent viral escape multiple gene 




There has been substantial research into different methods which enable the 
incorporation of multiple target sequences into a single construct in order to produce 
a coRNAi strategy which is able to both suppress the target virus and prevent the 
evolution of escape mutants. Methods of inducing coRNAi include STU and MTUs. 
The limitations of these methods include improper processing of long transcripts, and 
risk of toxicity caused by over expression. Previous research has also observed that 
shRNAs within an MTU produce a reduced level of suppression compared to 
identical shRNAs expressed from individual vectors (Hinton and Doran, 2008; 
McIntyre et al., 2011a). Proposed explanations for this include positional effects 
such as a reduced expression of the hairpin placed in the last position of the 
construct, and competition between hairpins expressed simultaneously for access to 
critical components of the RNAi pathway including Exportin-5 and RISC 
(Castanotto et al., 2007; McIntyre et al., 2011a).  
 
Chapter 4 investigated the use of a MTU method of coRNAi, with the main area of 
inquiry being whether the position given to a shRNA within the construct had an 
effect on the suppression produced. Hairpin competition was also investigated, with a 
comparison made between the expression of the shRNAs from the MTUs in chicken 
and mammalian cells. 
 
In order to determine if the positioning of hairpins within a MWH affects their 
expression, qRT-PCR was used to measure the amount of unprocessed shRNA 
expressed from a construct compared to the total expression of the siRNA sequence 
from that construct. As it is not possible to accurately separate the total expression 
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into the different sized RNA species and therefore calculate how much processed 
siRNA was present, only comparisons of shRNA and total expression will be made. 
To test if positioning a shRNA in the last cassette of a construct negatively affects 
the shRNAs expression, two three promoter-shRNA cassette constructs were 
produced. One of these contained the chU6-4 PBmiR107 cassette at the beginning 
and the other contained it at the end. No difference in expression was seen between 
the two different placements, suggesting that position has no effect on expression in 
either the chicken or mammalian cells. No evidence of positional effects was seen 
when comparing the expression levels of chU6-1 PAmiR107 when placed at the 
beginning of a MWH to when placed at the end of one. This shows that the lack of 
positional effects on PBmiR107 is not due to the strong chU6-4 promoter being able 
to counteract potentially negative impacts of being at the end of a construct. 
 
Analysis of the EGFP-fusion suppressive activity of the shRNAs agreed with the 
qRT-PCR expression data, and also with previously performed research. No 
difference was observed in the suppressive activity of either chU6-4 PBmiR107 or 
chU6-1 PAmiR107 when placed at the beginning or end of a construct. Previous 
research (McIntyre et al., 2011a) involved the production of MWH constructs 
containing two to four promoter-shRNA cassettes, which contained a shRNA in one 
position and empty cassettes in all others. The activity of the hairpin in all the 
different possible positions of these constructs was measured and no difference was 
found. Based on these results it is suggested that previous losses of efficiency in 
MWH constructs which have been attributed to positional effects are actually a result 




Evidence of the effects of hairpin competition was observed on the expression levels 
of the shRNAs when transfected into Vero cells but not DF1 cells. In Vero cells we 
observed a much higher total expression of chU6-3 NPmiR107 and chU6-1 
PAmiR107 when there was no chU6-4 PBmiR107 co-expressed. Previous research 
(Wise et al., 2007) which has compared expression strengths of the three promoters 
used found that chU6-4 was much stronger than chU6-1 in Vero cells, but not in DF1 
cells. It is suggested that the higher expression of PBmiR107 in Vero cells results in 
the weaker expressed hairpins being out competed for access to the RNAi pathway 
components, and results in a decrease in processing of the shRNAs to siRNAs.  
 
Evidence of hairpin competition was also seen in the analysis of the EGFP-fusion 
suppressive activity of the hairpins within the MWHs in Vero cells but not DF1s. It 
was observed that the presence of the chU6-4 PBmiR107 hairpin greatly reduced the 
suppressive activity of the chU6-3 NPmiR107 shRNA.  
 
The MWH constructs designed were found to suppress H1N1 influenza virus growth 
with varying efficiencies. It was found that the selection of shRNAs for inclusion 
into a MWH must be carefully considered, as not all shRNAs produce strong 
suppression of the target mRNA. It was observed that addition of a weakly 
suppressing shRNA reduces the net suppressive activity of the MWH, where addition 
of a shRNA with high suppressive activity increases the net suppression. It is 
surmised that the decrease in net suppressive activity caused by the inclusion of a 
weaker molecule is a result of hairpin competition. The shRNAs with weak 
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suppressive activity are processed through the RNAi pathway along with the more 
potent shRNAs, reducing the availability of the RNAi pathway proteins to the 
stronger molecules. The decreased rate at which the potent shRNAs are processed 
into mature siRNAs results in decreased suppression of their targets. The decrease in 
suppression we observed when comparing a MWH containing two efficient shRNAs 
to a MWH containing two efficient shRNAs and one weak shRNA was not found to 
be significant, however we propose that this is a result of the high antiviral potency 
of the first cassette in the MWH reducing the negative effect of the hairpin 
competition. 
 
Previous research into hairpin competition (Castanotto et al., 2007; Holen et al., 
2002; McIntyre et al., 2011a; McManus et al., 2002a) has found that co-expression 
of shRNAs results in the individual suppressive activity of each hairpin becoming 
progressively lower as the number of hairpins is increased. Castanotto et al. (2007) 
determined that the main competition observed between hairpins is for incorporation 
into RISC, though some competition may also occur for Exportin-5. McIntyre et al. 
(2011a) saw evidence of hairpin competition when looking at their individual 
suppressive activity but not when looking at the net suppressive activity of a MWH, 
however they tested only MWH constructs where all hairpins included were of high 
antiviral potency. They hypothesised that the inclusion of a shRNA with low 
suppressive activity would result in a reduction in the net suppressive activity of the 




The investigation into the expression of hairpins from a MTU construct provides 
further insight into the different variables which can impact the expression and 
suppressive activity of the hairpins. In agreement with published research, no 
evidence of the position in a MWH affecting either the expression or suppressive 
activity of the hairpins was found. This study has shown that it is important to 
carefully select the hairpins which are used to produce a MWH, as the presence of a 
hairpin which is a weaker suppressor than the others in the construct can result in a 
decrease in overall suppressive activity of the construct. Also, evidence of 
differences in the chU6-4, chU6-3 and chU6-1 promoter strengths were observed 
which supported previous findings (Wise et al., 2007), it is noted that as a result of 
these differences hairpin competition was seen to impact on the individual 
suppressive activity of the hairpins in Vero cells but not in DF1 cells. 
 
The MWH constructs produced during this investigation were not found to result in 
increased influenza A H1N1 virus suppression compared to a highly potent 
individual shRNA. However it is important to remember that these constructs are 
able to target multiple viral genes and therefore it is likely that the MWHs would 
provide better protection against viral escape in a prolonged infection.  
 
To build on the research presented here future work is suggested. A greater 
understanding of processing of hairpin RNA in DF1 and Vero cells could be obtained 
by using deep sequencing technology to identify the RNA species produced by 
processing, and by using Western blotting to measure the levels of the components of 
the RNAi pathway in the two different cell types and determine if there is a 
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relationship between the observed hairpin competition and the levels of one or more 
of these components. The observed inconsistencies between processing efficiency 
and viral suppressive ability of the miRloop shRNAs could be investigated by 
obtaining processing and viral suppression data for the constructs from the same cell 
line rather than two different ones. In order to determine if the multiple target 
sequences contained in the MWH constructs result in increased protection against 
virus escape an RNAi escape study could be performed.  
 
In summary, this thesis presents both a study of the individual optimisation of 
shRNAs, and the development and investigation of a coRNAi strategy for influenza 
A viruses. Individual shRNAs containing pre-miRNA derived loops were analysed 
for processing efficiency, EGFP-fusion plasmid suppressive activity, and H1N1 
influenza suppressive activity; and MWH constructs containing from two to three 
promoter-shRNA cassettes were analysed for expression, individual suppressive 
activity against EGFP-fusion plasmids, and net suppressive activity against H1N1 
influenza. Results showed that the effect of using pre-miRNA derived loop 
sequences depends both on the loop sequence and of the interaction between the loop 
and characteristics within the hairpin stem. The positioning of hairpins within 
MWHs was found to have no effect on their expression or suppressive activity; 
however the effects of hairpin competition showed that it is important to select 
hairpins with high antiviral potency for incorporation into MWHs, as inclusion of a 
poorly suppressing hairpin can decrease the net suppressive activity of the construct. 
Also, although none of the MWHs produced were found to have increased viral 
suppressive activity compared to a potent single shRNA, it is likely that the presence 
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of multiple target sequences within these MWHs would lead to increased resistance 
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Appendix A. Primers, Probes and oligonucleotides 
Primer Sequence 
TD175 (chU6-4 F) GAATTGTGGGACGGCGGAAG 
TD233 (SalI-chU6-4 F) GTCGACGAATTGTGGGACGGCGGAAG 
TD234  (Sal-chU6-3 F) GTCGACCAGACAGACGTCAGGCTTTC 
















































5S rRNA TGGGAATACCGGGTGCTGT 
TD318 (NP LNA) CtCCgAAgAAaTAaGAtCC 
TD345 (PB LNA) TTCaATgGTgGAaCAgATc 
U6 (U6 LNA) TtTAgTAttATgTGcTG 
TD203 (NP RNA) CUCCGAAGAAAUAAGAUCC 
TD287 (PB RNA) UUCAAUGGUGGAACAGAUC 
TD204 (PA RNA) UCAGGCACUCCUCAAUUGC 
 
a 
Letters in bold indicate pol III promoter termination signal 
b 
Letters with an underline indicate loop sequences 
c
 Letters in italic indicate a XhoI or SalI restriction enzyme recognition site 
d




Appendix B. Normalised Northern blot band intensities  
(a) standard loop shRNAs 
 siRNA shRNA Total 
shPB1-2257 1.95 0.29 2.24 
shNP-1498 0.58 0.34 0.92 
shNP-1496 1.69 0.92 2.61 
 
(b) PB miRloop shRNAs 
 siRNA shRNA Total 
shPB1-2257 0.91 0.07 0.98 
PBmiR122 0.73 0 0.73 
PBmiR107 2.32 0.91 3.23 
PBmiR19b 1.28 0.1 1.38 
 
(c) NP miRloop shRNAs 
 siRNA shRNA Total 
shNP-1496 1.21 1.13 2.34 
NPmiR122 0.56 0.07 0.63 
NPmiR107 0.87 1.82 2.69 
NPmiR19b 0.63 2.18 2.81 
 
 
 
